{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# GraphRAG Retrieval Evaluation"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Purpose\n",
    "The code implements an enhanced document retrieval system that combines vector similarity search with graph-based traversal to find relevant document chunks. Here's a detailed breakdown:\n",
    "\n",
    "1. **Vector Search & Similarity Scoring**\n",
    " - Converts the input query into a vector embedding\n",
    " - Performs similarity search against entity nodes in Neo4j\n",
    " - Creates a sorted dictionary of entity IDs and their similarity scores\n",
    " - Filters results based on a similarity threshold (default 0.8)\n",
    "\n",
    "2. **Graph Traversal Strategy**\n",
    "```sql\n",
    "    MATCH path = (n:Chunk)-[*1..{max_hops}]->(m:`__Entity__`)\n",
    "    WHERE m.id IN $ids\n",
    "```\n",
    " - Finds paths from document chunks to relevant entities\n",
    " - Limits path length to control traversal depth\n",
    " - Only considers entities that met the similarity threshold\n",
    "\n",
    "3. **Relevance Calculation**\n",
    "```sql\n",
    "    WITH n, min(length(path)) as distance, m\n",
    "    WITH n, distance, m.id as entity_id\n",
    "    WITH n, distance, entity_id, \n",
    "            CASE \n",
    "            WHEN entity_id IN $ids \n",
    "            THEN $similarity_scores[entity_id]\n",
    "            END as similarity\n",
    "```\n",
    " - Calculates shortest path length to each entity\n",
    " - Preserves original similarity scores from vector search\n",
    " - Combines structural proximity (distance) with semantic similarity\n",
    "\n",
    "4. **Result Ordering**\n",
    "```sql\n",
    "    ORDER BY similarity DESC, distance\n",
    "```\n",
    " - Prioritizes chunks with higher semantic similarity\n",
    " - Uses path distance as a secondary sorting criterion\n",
    " - Ensures most relevant chunks appear first\n",
    "\n",
    "5. **Output Format**\n",
    "```sql\n",
    "    RETURN n.text, n.fileName, n.page_number, n.position, entity_id, similarity\n",
    "```\n",
    " - Returns comprehensive chunk metadata:\n",
    "    - Text content\n",
    "    - Source file name\n",
    "    - Page number\n",
    "    - Position in document\n",
    "    - Associated entity ID\n",
    "    - Similarity score\n",
    "\n",
    "## Key Features\n",
    "- Hybrid retrieval approach combining:\n",
    "    - Vector-based semantic search\n",
    "    - Graph-based structural relationships\n",
    "- Configurable parameters:\n",
    "    - Similarity threshold\n",
    "    - Maximum path length\n",
    "    - Result limit\n",
    "- Deduplication of chunks\n",
    "- Ordered results by relevance\n",
    "- Rich metadata for each chunk"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 0: Environment Set Up"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "jupyter": {
     "is_executing": true
    }
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The .env file has been loaded\n"
     ]
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "from langchain_neo4j import Neo4jGraph\n",
    "from libs import create_vector_index\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "from conn import connect2Googlesheet,retrieval_rel_docs, get_avg_similarity_df,get_concatenate_df,clean_retrieved_files,apply_metrics,plot_metrics_and_roc\n",
    "from libs import context_builder, chunk_finder, enhanced_chunk_finder\n",
    "# plot figures in high resolution\n",
    "%config InlineBackend.figure_format = 'retina'\n",
    "# Force reload of the .env file\n",
    "try:\n",
    "    load_dotenv()\n",
    "    print(\"The .env file has been loaded\")\n",
    "except Exception as e:\n",
    "    print(\"The .env file has not been loaded. Reported error: \", e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Connected to Neo4j database successfully.\n",
      "The 'entities' index already exists.\n"
     ]
    }
   ],
   "source": [
    "# Connect to Neo4j database\n",
    "try:\n",
    "    graph = Neo4jGraph(\n",
    "        url=os.getenv(\"NEO4J_URL\"),\n",
    "        username=os.getenv(\"NEO4J_USERNAME\"),\n",
    "        password=os.getenv(\"NEO4J_PASSWORD\"),\n",
    "    )\n",
    "    print(\"Connected to Neo4j database successfully.\")\n",
    "except ValueError as e:\n",
    "    print(f\"Could not connect to Neo4j database: {e}\")\n",
    "\n",
    "# Check if the entities index exists\n",
    "index_name = \"entities\"\n",
    "query = \"SHOW INDEXES YIELD name, type WHERE type = 'VECTOR' AND name = $index_name\"\n",
    "\n",
    "result = graph.query(query, params={\"index_name\": index_name})\n",
    "if result:\n",
    "    print(\"The 'entities' index already exists.\")\n",
    "else:\n",
    "    create_vector_index(graph, \"entities\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 1: Create Vector Index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "âœ… Index 'entities' already exists with correct dimensions: 384\n"
     ]
    }
   ],
   "source": [
    "# Create a vector index for the entities if there doesn't exist one\n",
    "index_name = \"entities\"  # DO NOT CHANGE THIS VALUE\n",
    "create_vector_index(graph, index_name)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 2: Load Questions from Google Sheet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>condition</th>\n",
       "      <th>number</th>\n",
       "      <th>docs</th>\n",
       "      <th>Question</th>\n",
       "      <th>Mahmud's Note</th>\n",
       "      <th>status</th>\n",
       "      <th>comments</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>1</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Does early administration of neuromuscular blo...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>2</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Do patients with severe ARDS being treated wit...</td>\n",
       "      <td>Replace</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>3</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>In patients with moderate to severe ARDS, does...</td>\n",
       "      <td>Maybe this question: In patients with moderate...</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>4</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have ...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Wrong concept since PEEP by itself is mandator...</td>\n",
       "      <td>Does the use of neuromuscular blockers in pati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>5</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservat...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Check if studies defined conservative by CVP &lt;...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>6</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>Does a conservative fluid management strategy ...</td>\n",
       "      <td>Local question</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Does a conservative fluid management strategy ...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>7</td>\n",
       "      <td>ARDSNet</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal...</td>\n",
       "      <td>Like (just make it as question)</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Maybe make it two questions. Better not combin...</td>\n",
       "      <td>trying to make it yes/no questions</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>8</td>\n",
       "      <td>ARDSNet</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal...</td>\n",
       "      <td>Local</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Wrong question. Just make it as second point f...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>9</td>\n",
       "      <td>PROSEVA</td>\n",
       "      <td>Prone positioning sessions in patients with se...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>10</td>\n",
       "      <td>OSCILLATE</td>\n",
       "      <td>Does early application of high frequency oscil...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>11</td>\n",
       "      <td>ADRENAL</td>\n",
       "      <td>Patients with septic shock undergoing mechanic...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>12</td>\n",
       "      <td>ANNANE</td>\n",
       "      <td>Does a 7-day treatment with low doses of stero...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>13</td>\n",
       "      <td>APROCCHSS</td>\n",
       "      <td>Do patients who receive hydrocortisone plus fl...</td>\n",
       "      <td>Local</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>14</td>\n",
       "      <td>CORTICUS</td>\n",
       "      <td>Does steroids hasten the reversal of shock in ...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>15</td>\n",
       "      <td>HEAT</td>\n",
       "      <td>Does early administration of acetaminophen to ...</td>\n",
       "      <td>Consider make it general question as Does acet...</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>16</td>\n",
       "      <td>PROWESS</td>\n",
       "      <td>Does treatment with activated C protein signif...</td>\n",
       "      <td>Local</td>\n",
       "      <td>fixed and changed paper</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>17</td>\n",
       "      <td>ALBIOS</td>\n",
       "      <td>Albumin replacement in addition to crystalloid...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>18</td>\n",
       "      <td>SAFE</td>\n",
       "      <td>Does the use albumin for fluid resuscitation r...</td>\n",
       "      <td>Local</td>\n",
       "      <td>fixed and changed the paper</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>19</td>\n",
       "      <td>ProMISe</td>\n",
       "      <td>Did hemodynamic management according to a stri...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Sepsis</td>\n",
       "      <td>20</td>\n",
       "      <td>PROWESS-SHOCK</td>\n",
       "      <td>Does treatment with DrotAA (activated) signifi...</td>\n",
       "      <td>Local</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Cardiac Arrest</td>\n",
       "      <td>21</td>\n",
       "      <td>TTM2</td>\n",
       "      <td>In patients with coma after out-of-hospital ca...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Cardiac Arrest</td>\n",
       "      <td>22</td>\n",
       "      <td>TTM</td>\n",
       "      <td>In unconscious survivors of out-of-hospital ca...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Cardiac Arrest</td>\n",
       "      <td>23</td>\n",
       "      <td>HACA</td>\n",
       "      <td>Following patients that have been fully resusc...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>24</td>\n",
       "      <td>AID-ICU</td>\n",
       "      <td>Does treatment with haloperidol lead to a sign...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Can you check if that outcome used in the arti...</td>\n",
       "      <td>yes it was</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>25</td>\n",
       "      <td>MIND-USA</td>\n",
       "      <td>Does the use of ziprasidone as compared with p...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>26</td>\n",
       "      <td>SPICE-III</td>\n",
       "      <td>Is there more adverse events in ICU patients w...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>27</td>\n",
       "      <td>SPICE-III</td>\n",
       "      <td>Among patients undergoing mechanical ventilati...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Make it two questions. one about is it enough ...</td>\n",
       "      <td>noted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>28</td>\n",
       "      <td>SEDCOM</td>\n",
       "      <td>Was there a difference between dexmedetomidine...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>29</td>\n",
       "      <td>SEDCOM</td>\n",
       "      <td>Is bradycardia an adverse effect in critically...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>Make it direct questions \"What is the side eff...</td>\n",
       "      <td>We are trying to make it yes and no questions</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Delirium</td>\n",
       "      <td>30</td>\n",
       "      <td>SEDCOM</td>\n",
       "      <td>At comparable sedation levels, did dexmedetomi...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td>consider making it multiple questions</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>31</td>\n",
       "      <td>ESCPARDS</td>\n",
       "      <td>Does routine use of corticosteroids for persis...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>32</td>\n",
       "      <td>LCOTARDS</td>\n",
       "      <td>Is there a decrease in mortality rate among pa...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Cardiac Arrest</td>\n",
       "      <td>33</td>\n",
       "      <td>MHNOCA</td>\n",
       "      <td>Is there a better neurologic outcome between t...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Cardiac Arrest</td>\n",
       "      <td>34</td>\n",
       "      <td>BTCSCA</td>\n",
       "      <td>Does targeting a mean arterial blood pressure ...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Cardiac Arrest</td>\n",
       "      <td>35</td>\n",
       "      <td>OTCSCA</td>\n",
       "      <td>Does targeting a restrictive or liberal oxygen...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Delirium/Sepsis</td>\n",
       "      <td>36</td>\n",
       "      <td>DPSMVAS</td>\n",
       "      <td>Is there a difference in outcomes in patients ...</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "          condition  number           docs  \\\n",
       "0              ARDS       1       ACURASYS   \n",
       "1              ARDS       2       ACURASYS   \n",
       "2              ARDS       3           ROSE   \n",
       "3              ARDS       4           ROSE   \n",
       "4              ARDS       5          FACTT   \n",
       "5              ARDS       6          FACTT   \n",
       "6              ARDS       7        ARDSNet   \n",
       "7              ARDS       8        ARDSNet   \n",
       "8              ARDS       9        PROSEVA   \n",
       "9              ARDS      10      OSCILLATE   \n",
       "10           Sepsis      11        ADRENAL   \n",
       "11           Sepsis      12         ANNANE   \n",
       "12           Sepsis      13      APROCCHSS   \n",
       "13           Sepsis      14       CORTICUS   \n",
       "14           Sepsis      15           HEAT   \n",
       "15           Sepsis      16        PROWESS   \n",
       "16           Sepsis      17         ALBIOS   \n",
       "17           Sepsis      18           SAFE   \n",
       "18           Sepsis      19        ProMISe   \n",
       "19           Sepsis      20  PROWESS-SHOCK   \n",
       "20   Cardiac Arrest      21           TTM2   \n",
       "21   Cardiac Arrest      22            TTM   \n",
       "22   Cardiac Arrest      23           HACA   \n",
       "23         Delirium      24        AID-ICU   \n",
       "24         Delirium      25       MIND-USA   \n",
       "25         Delirium      26      SPICE-III   \n",
       "26         Delirium      27      SPICE-III   \n",
       "27         Delirium      28         SEDCOM   \n",
       "28         Delirium      29         SEDCOM   \n",
       "29         Delirium      30         SEDCOM   \n",
       "30             ARDS      31       ESCPARDS   \n",
       "31             ARDS      32       LCOTARDS   \n",
       "32   Cardiac Arrest      33         MHNOCA   \n",
       "33   Cardiac Arrest      34         BTCSCA   \n",
       "34   Cardiac Arrest      35         OTCSCA   \n",
       "35  Delirium/Sepsis      36        DPSMVAS   \n",
       "\n",
       "                                             Question  \\\n",
       "0   Does early administration of neuromuscular blo...   \n",
       "1   Do patients with severe ARDS being treated wit...   \n",
       "2   In patients with moderate to severe ARDS, does...   \n",
       "3   Do patients with moderate-to-severe ARDS have ...   \n",
       "4   Among patients with ALI/ARDS, does a conservat...   \n",
       "5   Does a conservative fluid management strategy ...   \n",
       "6   Does mechanical ventilation with a lower tidal...   \n",
       "7   Does mechanical ventilation with a lower tidal...   \n",
       "8   Prone positioning sessions in patients with se...   \n",
       "9   Does early application of high frequency oscil...   \n",
       "10  Patients with septic shock undergoing mechanic...   \n",
       "11  Does a 7-day treatment with low doses of stero...   \n",
       "12  Do patients who receive hydrocortisone plus fl...   \n",
       "13  Does steroids hasten the reversal of shock in ...   \n",
       "14  Does early administration of acetaminophen to ...   \n",
       "15  Does treatment with activated C protein signif...   \n",
       "16  Albumin replacement in addition to crystalloid...   \n",
       "17  Does the use albumin for fluid resuscitation r...   \n",
       "18  Did hemodynamic management according to a stri...   \n",
       "19  Does treatment with DrotAA (activated) signifi...   \n",
       "20  In patients with coma after out-of-hospital ca...   \n",
       "21  In unconscious survivors of out-of-hospital ca...   \n",
       "22  Following patients that have been fully resusc...   \n",
       "23  Does treatment with haloperidol lead to a sign...   \n",
       "24  Does the use of ziprasidone as compared with p...   \n",
       "25  Is there more adverse events in ICU patients w...   \n",
       "26  Among patients undergoing mechanical ventilati...   \n",
       "27  Was there a difference between dexmedetomidine...   \n",
       "28  Is bradycardia an adverse effect in critically...   \n",
       "29  At comparable sedation levels, did dexmedetomi...   \n",
       "30  Does routine use of corticosteroids for persis...   \n",
       "31  Is there a decrease in mortality rate among pa...   \n",
       "32  Is there a better neurologic outcome between t...   \n",
       "33  Does targeting a mean arterial blood pressure ...   \n",
       "34  Does targeting a restrictive or liberal oxygen...   \n",
       "35  Is there a difference in outcomes in patients ...   \n",
       "\n",
       "                                        Mahmud's Note  \\\n",
       "0                                                Like   \n",
       "1                                             Replace   \n",
       "2   Maybe this question: In patients with moderate...   \n",
       "3   Local question (not sure if this is the aim of...   \n",
       "4   Local question (not sure if this is the aim of...   \n",
       "5                                      Local question   \n",
       "6                     Like (just make it as question)   \n",
       "7                                               Local   \n",
       "8                                                Like   \n",
       "9                                                Like   \n",
       "10                                               Like   \n",
       "11                                               Like   \n",
       "12                                              Local   \n",
       "13                                               Like   \n",
       "14  Consider make it general question as Does acet...   \n",
       "15                                              Local   \n",
       "16                                               Like   \n",
       "17                                              Local   \n",
       "18                                               Like   \n",
       "19                                              Local   \n",
       "20                                                      \n",
       "21                                                      \n",
       "22                                                      \n",
       "23                                                      \n",
       "24                                                      \n",
       "25                                                      \n",
       "26                                                      \n",
       "27                                                      \n",
       "28                                                      \n",
       "29                                                      \n",
       "30                                                      \n",
       "31                                                      \n",
       "32                                                      \n",
       "33                                                      \n",
       "34                                                      \n",
       "35                                                      \n",
       "\n",
       "                         status  \\\n",
       "0                                 \n",
       "1                         fixed   \n",
       "2                         fixed   \n",
       "3                         fixed   \n",
       "4                         fixed   \n",
       "5                         fixed   \n",
       "6                         fixed   \n",
       "7                         fixed   \n",
       "8                                 \n",
       "9                                 \n",
       "10                                \n",
       "11                                \n",
       "12                        fixed   \n",
       "13                                \n",
       "14                        fixed   \n",
       "15      fixed and changed paper   \n",
       "16                                \n",
       "17  fixed and changed the paper   \n",
       "18                                \n",
       "19                        fixed   \n",
       "20                                \n",
       "21                                \n",
       "22                                \n",
       "23                                \n",
       "24                                \n",
       "25                                \n",
       "26                                \n",
       "27                                \n",
       "28                                \n",
       "29                                \n",
       "30                                \n",
       "31                                \n",
       "32                                \n",
       "33                                \n",
       "34                                \n",
       "35                                \n",
       "\n",
       "                                             comments  \\\n",
       "0                                                       \n",
       "1                                                       \n",
       "2                                                       \n",
       "3   Wrong concept since PEEP by itself is mandator...   \n",
       "4   Check if studies defined conservative by CVP <...   \n",
       "5   Does a conservative fluid management strategy ...   \n",
       "6   Maybe make it two questions. Better not combin...   \n",
       "7   Wrong question. Just make it as second point f...   \n",
       "8                                                       \n",
       "9                                                       \n",
       "10                                                      \n",
       "11                                                      \n",
       "12                                                      \n",
       "13                                                      \n",
       "14                                                      \n",
       "15                                                      \n",
       "16                                                      \n",
       "17                                                      \n",
       "18                                                      \n",
       "19                                                      \n",
       "20                                                      \n",
       "21                                                      \n",
       "22                                                      \n",
       "23  Can you check if that outcome used in the arti...   \n",
       "24                                                      \n",
       "25                                                      \n",
       "26  Make it two questions. one about is it enough ...   \n",
       "27                                                      \n",
       "28  Make it direct questions \"What is the side eff...   \n",
       "29             consider making it multiple questions    \n",
       "30                                                      \n",
       "31                                                      \n",
       "32                                                      \n",
       "33                                                      \n",
       "34                                                      \n",
       "35                                                      \n",
       "\n",
       "                                                       \n",
       "0                                                      \n",
       "1                                                      \n",
       "2                                                      \n",
       "3   Does the use of neuromuscular blockers in pati...  \n",
       "4                                                      \n",
       "5                                                      \n",
       "6                  trying to make it yes/no questions  \n",
       "7                                                      \n",
       "8                                                      \n",
       "9                                                      \n",
       "10                                                     \n",
       "11                                                     \n",
       "12                                                     \n",
       "13                                                     \n",
       "14                                                     \n",
       "15                                                     \n",
       "16                                                     \n",
       "17                                                     \n",
       "18                                                     \n",
       "19                                                     \n",
       "20                                                     \n",
       "21                                                     \n",
       "22                                                     \n",
       "23                                        yes it was   \n",
       "24                                                     \n",
       "25                                                     \n",
       "26                                              noted  \n",
       "27                                                     \n",
       "28     We are trying to make it yes and no questions   \n",
       "29                                                     \n",
       "30                                                     \n",
       "31                                                     \n",
       "32                                                     \n",
       "33                                                     \n",
       "34                                                     \n",
       "35                                                     "
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "spreadsheet = connect2Googlesheet()\n",
    "\n",
    "# Select the worksheet: relevance\n",
    "worksheet = spreadsheet.get_worksheet(2)\n",
    "\n",
    "# Define the expected headers\n",
    "# expected_headers = ['Header1', 'Header2', 'Header3']  # Replace with actual headers\n",
    "\n",
    "# Get all records as a list of dictionaries\n",
    "data = worksheet.get_all_records()\n",
    "\n",
    "# Convert to Pandas DataFrame\n",
    "df_MedQ = pd.DataFrame(data)\n",
    "df_MedQ.head(36)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 3: Relevance Check for Top K Questions"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "The [*1..{max_hops}] syntax in the Cypher query defines a variable-length relationship pattern in Neo4j.\n",
    "**Syntax Explanation**\n",
    "- `*` indicates a variable-length path\n",
    "- 1..{max_hops} specifies the range:\n",
    "    - 1 is the minimum length\n",
    "    - {max_hops} is the maximum length (passed as a parameter)\n",
    "\n",
    "**Purpose**\n",
    "1. Path Flexibility: It allows finding relationships between nodes that are both:\n",
    "    - Directly connected (1 hop)\n",
    "    - Indirectly connected (up to max_hops steps away)\n",
    "2. Example with max_hops=2:\n",
    "```python\n",
    "    (Chunk)-->(Entity)           // 1 hop\n",
    "    (Chunk)-->(Node)-->(Entity)  // 2 hops\n",
    "```\n",
    "3. Use Case in the Code:\n",
    "- The query finds chunks that are connected to relevant entities either:\n",
    "    - Directly (1 relationship away)\n",
    "    - Through intermediate nodes (up to max_hops relationships away)\n",
    "- This broadens the search context while maintaining control over the search depth\n",
    "\n",
    "**Practical Impact**\n",
    "```python\n",
    "    # With max_hops = 1 (direct connections only)\n",
    "    Chunk -> Entity\n",
    "\n",
    "    # With max_hops = 2 (includes indirect connections)\n",
    "    Chunk -> IntermediateNode -> Entity\n",
    "```\n",
    "This flexibility is particularly useful in knowledge graphs where relevant information might be connected through intermediate concepts or relationships."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Set pandas display options to show the full text content\n",
    "pd.set_option(\"display.max_colwidth\", None)\n",
    "pd.set_option(\"display.max_rows\", None)\n",
    "pd.set_option(\"display.max_columns\", None)\n",
    "# seeting up hyperparameters\n",
    "topk = 36  # 36 questions in total (10 papers only for ARDS)\n",
    "limit = 20\n",
    "similarity_threshold = 0.8\n",
    "max_hops = 1"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Uncomment the Following Code to Get **Updated** `results_df` Using `retrieval_rel_docs`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "results_df = retrieval_rel_docs(\n",
    "    graph,\n",
    "    df_MedQ,\n",
    "    top_k=topk,\n",
    "    limit=limit,\n",
    "    similarity_threshold=similarity_threshold,\n",
    "    max_hops=max_hops,\n",
    ")  # Retrieve relevant documents for each question"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "results_df.to_csv(\"./outputs/retrieved_docs_results.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 4: Compare Retrieval and Annotation Using Binary Metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Read the retrieved documents results from the csv file\n",
    "results_df = pd.read_csv(\"./outputs/retrieved_docs_results.csv\")\n",
    "# load relevant documents\n",
    "relevant_docs_df = pd.read_csv(\"./outputs/relevant_docs.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Get the average similarity for each question and aggregate the unique Retrieved Documents into a single column\n",
    "analysis_df = get_avg_similarity_df(results_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question Number</th>\n",
       "      <th>Question</th>\n",
       "      <th>Retrieved Files</th>\n",
       "      <th>Avg Similarity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Does early administration of neuromuscular blocking agents increases the ventilator free days?</td>\n",
       "      <td>[ENB.pdf, TOF-ARDS.pdf, ACURASYS.pdf, ESCNBC.pdf, FMWSCPARDS.pdf, SMDLTSWCI.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.822698</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?</td>\n",
       "      <td>[ROSE.pdf, ACURASYS.pdf, ESCNBC.pdf, OSCILLATE.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PTARDS.pdf, PPATDSHMA.pdf, EDPMARDSLPMV.pdf, APV.pdf, LSPA.pdf]</td>\n",
       "      <td>0.854614</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?</td>\n",
       "      <td>[ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, ESCNBC.pdf, BMIMSARDS.pdf, OSCILLATE.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, APV.pdf, ESCPARDS.pdf, LSPA.pdf]</td>\n",
       "      <td>0.847302</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who received an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?</td>\n",
       "      <td>[ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, BMIMSARDS.pdf, CEIIUPPSARDS.pdf, NBSARDS.pdf, PPATDSHMA.pdf]</td>\n",
       "      <td>0.812959</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?</td>\n",
       "      <td>[RARDS.pdf, FMWSCPARDS.pdf, DIHRFARDSNET.pdf, PAC-in-FACTT.pdf]</td>\n",
       "      <td>0.817033</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?</td>\n",
       "      <td>[FACTT.pdf, FMWSCPARDS.pdf, RARDS.pdf, ARDSSRDRFMS.pdf]</td>\n",
       "      <td>0.843431</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>[HARDST.pdf, ENB.pdf, ARDSSRDRFMS.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, ARDSNet.pdf, LSPA.pdf]</td>\n",
       "      <td>0.875296</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>[HARDST.pdf, ENB.pdf, ARDSSRDRFMS.pdf, FMWSCPARDS.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, ARDSNet.pdf, LSPA.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.857474</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Prone positioning sessions in patients with severe ARDS significantly decreased mortality?</td>\n",
       "      <td>[ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, ESCNBC.pdf, BMIMSARDS.pdf, FMWSCPARDS.pdf, CEIIUPPSARDS.pdf, NBSARDS.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, APV.pdf, LSPA.pdf]</td>\n",
       "      <td>0.853484</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?</td>\n",
       "      <td>[HARDST.pdf, ENB.pdf, OSCILLATE.pdf, BMIMSARDS.pdf, DDMLSMVICP.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, ARDSNet.pdf, LSPA.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.847682</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?</td>\n",
       "      <td>[ANNANE.pdf, CORTICUS.pdf, ADRENAL.pdf, HYPRESS.pdf, TRISS.pdf, SS3vsSS2.pdf, APROCCHSS.pdf, PLMALDHSS.pdf, FRESHS.pdf]</td>\n",
       "      <td>0.869297</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Does a 7-day treatment with low doses of steroids significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?</td>\n",
       "      <td>[PLMALDHSS.pdf, ANNANE.pdf, ADRENAL.pdf, CORTICUS.pdf]</td>\n",
       "      <td>0.830495</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?</td>\n",
       "      <td>[ANNANE.pdf, CORTICUS.pdf, ADRENAL.pdf, HYPRESS.pdf, APROCCHSS.pdf, PLMALDHSS.pdf]</td>\n",
       "      <td>0.819342</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Does steroids hasten the reversal of shock in patients whom had septic shock reversed?</td>\n",
       "      <td>[VASST.pdf, CORTICUS.pdf, ANNANE.pdf, ADRENAL.pdf, HYPRESS.pdf, SS3vsSS2.pdf, TRISS.pdf, NEvsVP.pdf, APROCCHSS.pdf, PLMALDHSS.pdf, FRESHS.pdf]</td>\n",
       "      <td>0.826625</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Does early administration of acetaminophen to treat fever affect the number of ICU-free days</td>\n",
       "      <td>[HEAT.pdf]</td>\n",
       "      <td>0.887364</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?</td>\n",
       "      <td>[PROWESS.pdf, ULS.pdf, EDIS.pdf, CABS.pdf, LOVIT.pdf, SADASS.pdf, ALBIOS.pdf, Rivers Trial.pdf, PROWESS-SHOCK.pdf, APROCCHSS.pdf, PLMALDHSS.pdf, EDvsLSMENDS.pdf]</td>\n",
       "      <td>0.849581</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival</td>\n",
       "      <td>[ULS.pdf, ALBIOS.pdf, SS3vsSS2.pdf]</td>\n",
       "      <td>0.873086</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?</td>\n",
       "      <td>[SAFE.pdf, FEAST.pdf, SS3vsSS2.pdf, SADASS.pdf, ALBIOS.pdf, DDS.pdf]</td>\n",
       "      <td>0.845052</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?</td>\n",
       "      <td>[Rivers Trial.pdf, ProCESS.pdf, ARISE.pdf]</td>\n",
       "      <td>0.812549</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?</td>\n",
       "      <td>[PROWESS-SHOCK.pdf, APROCCHSS.pdf, SADASS.pdf]</td>\n",
       "      <td>0.842357</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?</td>\n",
       "      <td>[RIC.pdf, HACA-LA.pdf, TCAIHCA.pdf, TTM2.pdf, CETHACA.pdf, HACA.pdf, MPOHCAUSPITHRCA.pdf, THvsTN.pdf, HNPCASR.pdf]</td>\n",
       "      <td>0.891963</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?</td>\n",
       "      <td>[RIC.pdf, HACA-LA.pdf, TCAIHCA.pdf, TTM2.pdf, HACA.pdf, TTM.pdf, THvsTN.pdf, HNPCASR.pdf]</td>\n",
       "      <td>0.882604</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favorable neurologic outcome and reduce mortality?</td>\n",
       "      <td>[RIC.pdf, HACA-LA.pdf, TCAIHCA.pdf, CETHACA.pdf, TTM2.pdf, HACA.pdf, MPOHCAUSPITHRCA.pdf, THvsTN.pdf, HNPCASR.pdf]</td>\n",
       "      <td>0.879469</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?</td>\n",
       "      <td>[DIICU.pdf, AID-ICU.pdf, RUSGATICUD.pdf, RAEATICU.pdf, AMTD.pdf]</td>\n",
       "      <td>0.865217</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?</td>\n",
       "      <td>[DIICU.pdf, AID-ICU.pdf, RUSGATICUD.pdf, AMTD.pdf, RAEATICU.pdf]</td>\n",
       "      <td>0.815780</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>Is there more adverse events in ICU patients who recieved early dexmedetomidine?</td>\n",
       "      <td>[SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, DIICU.pdf, ESDDVCIP.pdf, HDDSICU.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.845843</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?</td>\n",
       "      <td>[SPICE-III.pdf, RDSCI.pdf, ESDDVCIP.pdf, SEDCOM.pdf, EDvsLSMENDS.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.892401</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?</td>\n",
       "      <td>[SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, ESDDVCIP.pdf, SEDCOM.pdf, EDvsLSMENDS.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.892393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?</td>\n",
       "      <td>[SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, ESDDVCIP.pdf, SMDLTSWCI.pdf, SEDCOM.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.840727</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?</td>\n",
       "      <td>[SPICE-III.pdf, RDSCI.pdf, ESDDVCIP.pdf, EDvsLSMENDS.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.870136</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>31</td>\n",
       "      <td>Does routine use of corticosteroids for persistent ARDS over prolonged periods have increased survival rate?</td>\n",
       "      <td>[HARDST.pdf, ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, CCCARDS.pdf, BMIMSARDS.pdf, OSCILLATE.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, APV.pdf, ESCPARDS.pdf, LSPA.pdf]</td>\n",
       "      <td>0.827539</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>32</td>\n",
       "      <td>Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?</td>\n",
       "      <td>[ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, BMIMSARDS.pdf, OSCILLATE.pdf, CEIIUPPSARDS.pdf, NBSARDS.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, CHEST.pdf, ESCPARDS.pdf, PROSEVA.pdf]</td>\n",
       "      <td>0.841921</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>33</td>\n",
       "      <td>Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??</td>\n",
       "      <td>[THvsTN.pdf, CETHACA.pdf]</td>\n",
       "      <td>0.852407</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>34</td>\n",
       "      <td>Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?</td>\n",
       "      <td>[RIC.pdf, CAC.pdf, SEPSISPAM.pdf, OHCA.pdf, EXACT.pdf, MCAU.pdf, CETHACA.pdf, IHCA.pdf, BTCSCA.pdf, THvsTN.pdf]</td>\n",
       "      <td>0.843637</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>35</td>\n",
       "      <td>Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?</td>\n",
       "      <td>[RIC.pdf, CAC.pdf, HACA-LA.pdf, OHCA.pdf, EXACT.pdf, CETHACA.pdf, BTCSCA.pdf, THvsTN.pdf]</td>\n",
       "      <td>0.843511</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?</td>\n",
       "      <td>[SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, ESDDVCIP.pdf, SMDLTSWCI.pdf, EDvsLSMENDS.pdf, DDS.pdf, ETSDMV.pdf]</td>\n",
       "      <td>0.850530</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Question Number  \\\n",
       "0                 1   \n",
       "1                 2   \n",
       "2                 3   \n",
       "3                 4   \n",
       "4                 5   \n",
       "5                 6   \n",
       "6                 7   \n",
       "7                 8   \n",
       "8                 9   \n",
       "9                10   \n",
       "10               11   \n",
       "11               12   \n",
       "12               13   \n",
       "13               14   \n",
       "14               15   \n",
       "15               16   \n",
       "16               17   \n",
       "17               18   \n",
       "18               19   \n",
       "19               20   \n",
       "20               21   \n",
       "21               22   \n",
       "22               23   \n",
       "23               24   \n",
       "24               25   \n",
       "25               26   \n",
       "26               27   \n",
       "27               28   \n",
       "28               29   \n",
       "29               30   \n",
       "30               31   \n",
       "31               32   \n",
       "32               33   \n",
       "33               34   \n",
       "34               35   \n",
       "35               36   \n",
       "\n",
       "                                                                                                                                                                                                                                     Question  \\\n",
       "0                                                                                                                                              Does early administration of neuromuscular blocking agents increases the ventilator free days?   \n",
       "1                                                                                                                               Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?   \n",
       "2                                                                                                                            In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?   \n",
       "3   Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who received an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?   \n",
       "4                                                                               Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?   \n",
       "5                                                                                                                       Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?   \n",
       "6                                                                                         Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?   \n",
       "7                                                                   Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?   \n",
       "8                                                                                                                                                  Prone positioning sessions in patients with severe ARDS significantly decreased mortality?   \n",
       "9                                                                                                 Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?   \n",
       "10                                                                                                  Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?   \n",
       "11                                               Does a 7-day treatment with low doses of steroids significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?   \n",
       "12                                                                                                         Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?   \n",
       "13                                                                                                                                                     Does steroids hasten the reversal of shock in patients whom had septic shock reversed?   \n",
       "14                                                                                                                                               Does early administration of acetaminophen to treat fever affect the number of ICU-free days   \n",
       "15                                                                                                                                     Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?   \n",
       "16                                                                                                                      Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival   \n",
       "17                                                                                                                              Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?   \n",
       "18                                                                                                                    Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?   \n",
       "19                                                                                           Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?   \n",
       "20                                                                            In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?   \n",
       "21                                 In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?   \n",
       "22              Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favorable neurologic outcome and reduce mortality?   \n",
       "23                                                      Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?   \n",
       "24                                                      Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?   \n",
       "25                                                                                                                                                           Is there more adverse events in ICU patients who recieved early dexmedetomidine?   \n",
       "26                                                                   Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?   \n",
       "27                                                                                                   Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?   \n",
       "28                                                                                                                                                     Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?   \n",
       "29                                                            At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?   \n",
       "30                                                                                                                              Does routine use of corticosteroids for persistent ARDS over prolonged periods have increased survival rate?    \n",
       "31                                                                                                                Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?   \n",
       "32                                                  Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??   \n",
       "33                                                                                                             Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?   \n",
       "34                                               Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?   \n",
       "35                                                                                                  Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?   \n",
       "\n",
       "                                                                                                                                                                                              Retrieved Files  \\\n",
       "0                                                                                          [ENB.pdf, TOF-ARDS.pdf, ACURASYS.pdf, ESCNBC.pdf, FMWSCPARDS.pdf, SMDLTSWCI.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]   \n",
       "1                                                          [ROSE.pdf, ACURASYS.pdf, ESCNBC.pdf, OSCILLATE.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PTARDS.pdf, PPATDSHMA.pdf, EDPMARDSLPMV.pdf, APV.pdf, LSPA.pdf]   \n",
       "2                [ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, ESCNBC.pdf, BMIMSARDS.pdf, OSCILLATE.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, APV.pdf, ESCPARDS.pdf, LSPA.pdf]   \n",
       "3                                                                                                         [ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, BMIMSARDS.pdf, CEIIUPPSARDS.pdf, NBSARDS.pdf, PPATDSHMA.pdf]   \n",
       "4                                                                                                                                             [RARDS.pdf, FMWSCPARDS.pdf, DIHRFARDSNET.pdf, PAC-in-FACTT.pdf]   \n",
       "5                                                                                                                                                     [FACTT.pdf, FMWSCPARDS.pdf, RARDS.pdf, ARDSSRDRFMS.pdf]   \n",
       "6                                                                                   [HARDST.pdf, ENB.pdf, ARDSSRDRFMS.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, ARDSNet.pdf, LSPA.pdf]   \n",
       "7                                        [HARDST.pdf, ENB.pdf, ARDSSRDRFMS.pdf, FMWSCPARDS.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, ARDSNet.pdf, LSPA.pdf, ETSDMV.pdf]   \n",
       "8                                            [ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, ESCNBC.pdf, BMIMSARDS.pdf, FMWSCPARDS.pdf, CEIIUPPSARDS.pdf, NBSARDS.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, APV.pdf, LSPA.pdf]   \n",
       "9                                        [HARDST.pdf, ENB.pdf, OSCILLATE.pdf, BMIMSARDS.pdf, DDMLSMVICP.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, ARDSNet.pdf, LSPA.pdf, ETSDMV.pdf]   \n",
       "10                                                                                    [ANNANE.pdf, CORTICUS.pdf, ADRENAL.pdf, HYPRESS.pdf, TRISS.pdf, SS3vsSS2.pdf, APROCCHSS.pdf, PLMALDHSS.pdf, FRESHS.pdf]   \n",
       "11                                                                                                                                                     [PLMALDHSS.pdf, ANNANE.pdf, ADRENAL.pdf, CORTICUS.pdf]   \n",
       "12                                                                                                                         [ANNANE.pdf, CORTICUS.pdf, ADRENAL.pdf, HYPRESS.pdf, APROCCHSS.pdf, PLMALDHSS.pdf]   \n",
       "13                                                             [VASST.pdf, CORTICUS.pdf, ANNANE.pdf, ADRENAL.pdf, HYPRESS.pdf, SS3vsSS2.pdf, TRISS.pdf, NEvsVP.pdf, APROCCHSS.pdf, PLMALDHSS.pdf, FRESHS.pdf]   \n",
       "14                                                                                                                                                                                                 [HEAT.pdf]   \n",
       "15                                          [PROWESS.pdf, ULS.pdf, EDIS.pdf, CABS.pdf, LOVIT.pdf, SADASS.pdf, ALBIOS.pdf, Rivers Trial.pdf, PROWESS-SHOCK.pdf, APROCCHSS.pdf, PLMALDHSS.pdf, EDvsLSMENDS.pdf]   \n",
       "16                                                                                                                                                                        [ULS.pdf, ALBIOS.pdf, SS3vsSS2.pdf]   \n",
       "17                                                                                                                                       [SAFE.pdf, FEAST.pdf, SS3vsSS2.pdf, SADASS.pdf, ALBIOS.pdf, DDS.pdf]   \n",
       "18                                                                                                                                                                 [Rivers Trial.pdf, ProCESS.pdf, ARISE.pdf]   \n",
       "19                                                                                                                                                             [PROWESS-SHOCK.pdf, APROCCHSS.pdf, SADASS.pdf]   \n",
       "20                                                                                         [RIC.pdf, HACA-LA.pdf, TCAIHCA.pdf, TTM2.pdf, CETHACA.pdf, HACA.pdf, MPOHCAUSPITHRCA.pdf, THvsTN.pdf, HNPCASR.pdf]   \n",
       "21                                                                                                                  [RIC.pdf, HACA-LA.pdf, TCAIHCA.pdf, TTM2.pdf, HACA.pdf, TTM.pdf, THvsTN.pdf, HNPCASR.pdf]   \n",
       "22                                                                                         [RIC.pdf, HACA-LA.pdf, TCAIHCA.pdf, CETHACA.pdf, TTM2.pdf, HACA.pdf, MPOHCAUSPITHRCA.pdf, THvsTN.pdf, HNPCASR.pdf]   \n",
       "23                                                                                                                                           [DIICU.pdf, AID-ICU.pdf, RUSGATICUD.pdf, RAEATICU.pdf, AMTD.pdf]   \n",
       "24                                                                                                                                           [DIICU.pdf, AID-ICU.pdf, RUSGATICUD.pdf, AMTD.pdf, RAEATICU.pdf]   \n",
       "25                                                                                                               [SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, DIICU.pdf, ESDDVCIP.pdf, HDDSICU.pdf, ETSDMV.pdf]   \n",
       "26                                                                                                    [SPICE-III.pdf, RDSCI.pdf, ESDDVCIP.pdf, SEDCOM.pdf, EDvsLSMENDS.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]   \n",
       "27                                                                                    [SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, ESDDVCIP.pdf, SEDCOM.pdf, EDvsLSMENDS.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]   \n",
       "28                                                                                      [SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, ESDDVCIP.pdf, SMDLTSWCI.pdf, SEDCOM.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]   \n",
       "29                                                                                                                [SPICE-III.pdf, RDSCI.pdf, ESDDVCIP.pdf, EDvsLSMENDS.pdf, DDS.pdf, HDDSICU.pdf, ETSDMV.pdf]   \n",
       "30  [HARDST.pdf, ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, CCCARDS.pdf, BMIMSARDS.pdf, OSCILLATE.pdf, NBSARDS.pdf, CEIIUPPSARDS.pdf, PPATDSHMA.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, APV.pdf, ESCPARDS.pdf, LSPA.pdf]   \n",
       "31                                     [ROSE.pdf, TOF-ARDS.pdf, ACURASYS.pdf, BMIMSARDS.pdf, OSCILLATE.pdf, CEIIUPPSARDS.pdf, NBSARDS.pdf, RARDS.pdf, EDPMARDSLPMV.pdf, CHEST.pdf, ESCPARDS.pdf, PROSEVA.pdf]   \n",
       "32                                                                                                                                                                                  [THvsTN.pdf, CETHACA.pdf]   \n",
       "33                                                                                            [RIC.pdf, CAC.pdf, SEPSISPAM.pdf, OHCA.pdf, EXACT.pdf, MCAU.pdf, CETHACA.pdf, IHCA.pdf, BTCSCA.pdf, THvsTN.pdf]   \n",
       "34                                                                                                                  [RIC.pdf, CAC.pdf, HACA-LA.pdf, OHCA.pdf, EXACT.pdf, CETHACA.pdf, BTCSCA.pdf, THvsTN.pdf]   \n",
       "35                                                                                              [SPICE-III.pdf, RDSCI.pdf, DDMLSMVICP.pdf, ESDDVCIP.pdf, SMDLTSWCI.pdf, EDvsLSMENDS.pdf, DDS.pdf, ETSDMV.pdf]   \n",
       "\n",
       "    Avg Similarity  \n",
       "0         0.822698  \n",
       "1         0.854614  \n",
       "2         0.847302  \n",
       "3         0.812959  \n",
       "4         0.817033  \n",
       "5         0.843431  \n",
       "6         0.875296  \n",
       "7         0.857474  \n",
       "8         0.853484  \n",
       "9         0.847682  \n",
       "10        0.869297  \n",
       "11        0.830495  \n",
       "12        0.819342  \n",
       "13        0.826625  \n",
       "14        0.887364  \n",
       "15        0.849581  \n",
       "16        0.873086  \n",
       "17        0.845052  \n",
       "18        0.812549  \n",
       "19        0.842357  \n",
       "20        0.891963  \n",
       "21        0.882604  \n",
       "22        0.879469  \n",
       "23        0.865217  \n",
       "24        0.815780  \n",
       "25        0.845843  \n",
       "26        0.892401  \n",
       "27        0.892393  \n",
       "28        0.840727  \n",
       "29        0.870136  \n",
       "30        0.827539  \n",
       "31        0.841921  \n",
       "32        0.852407  \n",
       "33        0.843637  \n",
       "34        0.843511  \n",
       "35        0.850530  "
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "analysis_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>Ques</th>\n",
       "      <th>Docs</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>Relevance Q1</td>\n",
       "      <td>ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>Relevance Q2</td>\n",
       "      <td>ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>Relevance Q3</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>Relevance Q4</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>Relevance Q5</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>5</td>\n",
       "      <td>Relevance Q6</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6</td>\n",
       "      <td>Relevance Q7</td>\n",
       "      <td>APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>Relevance Q8</td>\n",
       "      <td>APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>8</td>\n",
       "      <td>Relevance Q9</td>\n",
       "      <td>ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, PPATDSHMA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>9</td>\n",
       "      <td>Relevance Q10</td>\n",
       "      <td>HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-ICU, SEDCOM</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>Relevance Q11</td>\n",
       "      <td>ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SEDCOM, APROCCHSS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>Relevance Q12</td>\n",
       "      <td>ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, MIND-USA, NEvsVP, EDvsLSMENDS, ESDDVCIP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, APROCCHSS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>12</td>\n",
       "      <td>Relevance Q13</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>Relevance Q14</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>Relevance Q15</td>\n",
       "      <td>ESDDVCIP, HEAT</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>Relevance Q16</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>Relevance Q17</td>\n",
       "      <td>RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>Relevance Q18</td>\n",
       "      <td>SAFE, FRESHS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>Relevance Q19</td>\n",
       "      <td>RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>Relevance Q20</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20</td>\n",
       "      <td>Relevance Q21</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>21</td>\n",
       "      <td>Relevance Q22</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>22</td>\n",
       "      <td>Relevance Q23</td>\n",
       "      <td>MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SRRCTTHNPCAP, HACA, ITMNCA, SOPA-III, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>23</td>\n",
       "      <td>Relevance Q24</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>24</td>\n",
       "      <td>Relevance Q25</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>25</td>\n",
       "      <td>Relevance Q26</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>26</td>\n",
       "      <td>Relevance Q27</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>27</td>\n",
       "      <td>Relevance Q28</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>28</td>\n",
       "      <td>Relevance Q29</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>29</td>\n",
       "      <td>Relevance Q30</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>30</td>\n",
       "      <td>Relevance Q31</td>\n",
       "      <td>ESDDVCIP, ESCPARDS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>31</td>\n",
       "      <td>Relevance Q32</td>\n",
       "      <td>ESDDVCIP, LCOTARDS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>32</td>\n",
       "      <td>Relevance Q33</td>\n",
       "      <td>ESDDVCIP, MHNOCA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>33</td>\n",
       "      <td>Relevance Q34</td>\n",
       "      <td>BTCSCA</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>34</td>\n",
       "      <td>Relevance Q35</td>\n",
       "      <td>OTCSCA, SPICE-III, HDDSICU, ESDDVCIP</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>35</td>\n",
       "      <td>Relevance Q36</td>\n",
       "      <td>ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVCIP, DPSMVAS, DIICU, RAEATICU, SPICE-III, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0           Ques  \\\n",
       "0            0   Relevance Q1   \n",
       "1            1   Relevance Q2   \n",
       "2            2   Relevance Q3   \n",
       "3            3   Relevance Q4   \n",
       "4            4   Relevance Q5   \n",
       "5            5   Relevance Q6   \n",
       "6            6   Relevance Q7   \n",
       "7            7   Relevance Q8   \n",
       "8            8   Relevance Q9   \n",
       "9            9  Relevance Q10   \n",
       "10          10  Relevance Q11   \n",
       "11          11  Relevance Q12   \n",
       "12          12  Relevance Q13   \n",
       "13          13  Relevance Q14   \n",
       "14          14  Relevance Q15   \n",
       "15          15  Relevance Q16   \n",
       "16          16  Relevance Q17   \n",
       "17          17  Relevance Q18   \n",
       "18          18  Relevance Q19   \n",
       "19          19  Relevance Q20   \n",
       "20          20  Relevance Q21   \n",
       "21          21  Relevance Q22   \n",
       "22          22  Relevance Q23   \n",
       "23          23  Relevance Q24   \n",
       "24          24  Relevance Q25   \n",
       "25          25  Relevance Q26   \n",
       "26          26  Relevance Q27   \n",
       "27          27  Relevance Q28   \n",
       "28          28  Relevance Q29   \n",
       "29          29  Relevance Q30   \n",
       "30          30  Relevance Q31   \n",
       "31          31  Relevance Q32   \n",
       "32          32  Relevance Q33   \n",
       "33          33  Relevance Q34   \n",
       "34          34  Relevance Q35   \n",
       "35          35  Relevance Q36   \n",
       "\n",
       "                                                                                                                                                                            Docs  \n",
       "0                                                                                                ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS  \n",
       "1                                                                                        ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS  \n",
       "2                                                                                                                      ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS  \n",
       "3                                                                                                                      ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS  \n",
       "4                                                                                                                                   FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS  \n",
       "5                                                                                                                                   FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS  \n",
       "6                                                                                                                                  APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET  \n",
       "7                                                                                                              APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsARDSNET, DIHRFARDSNET  \n",
       "8                                                                                                                         ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, PPATDSHMA  \n",
       "9                                                                                                                       HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-ICU, SEDCOM  \n",
       "10                                                                        ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SEDCOM, APROCCHSS  \n",
       "11  ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, MIND-USA, NEvsVP, EDvsLSMENDS, ESDDVCIP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, APROCCHSS  \n",
       "12                                                                                                              ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS  \n",
       "13                                                                                                              ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS  \n",
       "14                                                                                                                                                                ESDDVCIP, HEAT  \n",
       "15                                                                                                                                      ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS  \n",
       "16                                                                                                                              RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS  \n",
       "17                                                                                                                                                                  SAFE, FRESHS  \n",
       "18                                                                                                                             RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial  \n",
       "19                                                                                                                                      ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS  \n",
       "20                                                                           MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA  \n",
       "21                                                                           MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA  \n",
       "22                                                            MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SRRCTTHNPCAP, HACA, ITMNCA, SOPA-III, HNPCASR, VMOCA, TCAIHCA, HACA-LA  \n",
       "23                                                                   ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, RDSCI, DDMLSMVICP  \n",
       "24                                                           ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SEDCOM, RDSCI, DDMLSMVICP  \n",
       "25                ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, RDSCI, DDMLSMVICP  \n",
       "26        ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, DDMLSMVICP  \n",
       "27                 ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP  \n",
       "28                           ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP  \n",
       "29                           ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP  \n",
       "30                                                                                                                                                            ESDDVCIP, ESCPARDS  \n",
       "31                                                                                                                                                            ESDDVCIP, LCOTARDS  \n",
       "32                                                                                                                                                              ESDDVCIP, MHNOCA  \n",
       "33                                                                                                                                                                        BTCSCA  \n",
       "34                                                                                                                                          OTCSCA, SPICE-III, HDDSICU, ESDDVCIP  \n",
       "35                                                              ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVCIP, DPSMVAS, DIICU, RAEATICU, SPICE-III, SEDCOM, RDSCI, DDMLSMVICP  "
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relevant_docs_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Get the concatenated dataframe\n",
    "concatenated_df = get_concatenate_df(analysis_df, relevant_docs_df, topk=36)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "concatenated_df = pd.concat(\n",
    "    [analysis_df.iloc[:topk], relevant_docs_df.iloc[:topk]], axis=1\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "concatenated_df = concatenated_df[\n",
    "    [\"Question Number\", \"Question\", \"Docs\", \"Retrieved Files\", \"Avg Similarity\"]\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Question Number      int64\n",
       "Question            object\n",
       "Docs                object\n",
       "Retrieved Files     object\n",
       "Avg Similarity     float64\n",
       "dtype: object"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "concatenated_df.dtypes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "concatenated_df = clean_retrieved_files(concatenated_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question Number</th>\n",
       "      <th>Question</th>\n",
       "      <th>Docs</th>\n",
       "      <th>Retrieved Files</th>\n",
       "      <th>Avg Similarity</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Does early administration of neuromuscular blocking agents increases the ventilator free days?</td>\n",
       "      <td>ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ENB, TOF-ARDS, ACURASYS, ESCNBC, FMWSCPARDS, SMDLTSWCI, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.822698</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?</td>\n",
       "      <td>ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ROSE, ACURASYS, ESCNBC, OSCILLATE, NBSARDS, CEIIUPPSARDS, PTARDS, PPATDSHMA, EDPMARDSLPMV, APV, LSPA</td>\n",
       "      <td>0.854614</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA</td>\n",
       "      <td>0.847302</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who received an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, CEIIUPPSARDS, NBSARDS, PPATDSHMA</td>\n",
       "      <td>0.812959</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "      <td>RARDS, FMWSCPARDS, DIHRFARDSNET, PAC-in-FACTT</td>\n",
       "      <td>0.817033</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "      <td>FACTT, FMWSCPARDS, RARDS, ARDSSRDRFMS</td>\n",
       "      <td>0.843431</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "      <td>HARDST, ENB, ARDSSRDRFMS, NBSARDS, CEIIUPPSARDS, RARDS, EDPMARDSLPMV, ARDSNet, LSPA</td>\n",
       "      <td>0.875296</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "      <td>HARDST, ENB, ARDSSRDRFMS, FMWSCPARDS, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV</td>\n",
       "      <td>0.857474</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Prone positioning sessions in patients with severe ARDS significantly decreased mortality?</td>\n",
       "      <td>ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, PPATDSHMA</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, FMWSCPARDS, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, APV, LSPA</td>\n",
       "      <td>0.853484</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?</td>\n",
       "      <td>HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-ICU, SEDCOM</td>\n",
       "      <td>HARDST, ENB, OSCILLATE, BMIMSARDS, DDMLSMVICP, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV</td>\n",
       "      <td>0.847682</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?</td>\n",
       "      <td>ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SEDCOM, APROCCHSS</td>\n",
       "      <td>ANNANE, CORTICUS, ADRENAL, HYPRESS, TRISS, SS3vsSS2, APROCCHSS, PLMALDHSS, FRESHS</td>\n",
       "      <td>0.869297</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Does a 7-day treatment with low doses of steroids significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?</td>\n",
       "      <td>ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, MIND-USA, NEvsVP, EDvsLSMENDS, ESDDVCIP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, APROCCHSS</td>\n",
       "      <td>PLMALDHSS, ANNANE, ADRENAL, CORTICUS</td>\n",
       "      <td>0.830495</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS</td>\n",
       "      <td>ANNANE, CORTICUS, ADRENAL, HYPRESS, APROCCHSS, PLMALDHSS</td>\n",
       "      <td>0.819342</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Does steroids hasten the reversal of shock in patients whom had septic shock reversed?</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS</td>\n",
       "      <td>VASST, CORTICUS, ANNANE, ADRENAL, HYPRESS, SS3vsSS2, TRISS, NEvsVP, APROCCHSS, PLMALDHSS, FRESHS</td>\n",
       "      <td>0.826625</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Does early administration of acetaminophen to treat fever affect the number of ICU-free days</td>\n",
       "      <td>ESDDVCIP, HEAT</td>\n",
       "      <td>HEAT</td>\n",
       "      <td>0.887364</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "      <td>PROWESS, ULS, EDIS, CABS, LOVIT, SADASS, ALBIOS, Rivers Trial, PROWESS-SHOCK, APROCCHSS, PLMALDHSS, EDvsLSMENDS</td>\n",
       "      <td>0.849581</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival</td>\n",
       "      <td>RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS</td>\n",
       "      <td>ULS, ALBIOS, SS3vsSS2</td>\n",
       "      <td>0.873086</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?</td>\n",
       "      <td>SAFE, FRESHS</td>\n",
       "      <td>SAFE, FEAST, SS3vsSS2, SADASS, ALBIOS, DDS</td>\n",
       "      <td>0.845052</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?</td>\n",
       "      <td>RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial</td>\n",
       "      <td>Rivers Trial, ProCESS, ARISE</td>\n",
       "      <td>0.812549</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "      <td>PROWESS-SHOCK, APROCCHSS, SADASS</td>\n",
       "      <td>0.842357</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, TTM2, CETHACA, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR</td>\n",
       "      <td>0.891963</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, TTM2, HACA, TTM, THvsTN, HNPCASR</td>\n",
       "      <td>0.882604</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favorable neurologic outcome and reduce mortality?</td>\n",
       "      <td>MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SRRCTTHNPCAP, HACA, ITMNCA, SOPA-III, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, CETHACA, TTM2, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR</td>\n",
       "      <td>0.879469</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, RDSCI, DDMLSMVICP</td>\n",
       "      <td>DIICU, AID-ICU, RUSGATICUD, RAEATICU, AMTD</td>\n",
       "      <td>0.865217</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "      <td>DIICU, AID-ICU, RUSGATICUD, AMTD, RAEATICU</td>\n",
       "      <td>0.815780</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>Is there more adverse events in ICU patients who recieved early dexmedetomidine?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, DIICU, ESDDVCIP, HDDSICU, ETSDMV</td>\n",
       "      <td>0.845843</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.892401</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.892393</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, SEDCOM, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.840727</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, ESDDVCIP, EDvsLSMENDS, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.870136</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>31</td>\n",
       "      <td>Does routine use of corticosteroids for persistent ARDS over prolonged periods have increased survival rate?</td>\n",
       "      <td>ESDDVCIP, ESCPARDS</td>\n",
       "      <td>HARDST, ROSE, TOF-ARDS, ACURASYS, CCCARDS, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA</td>\n",
       "      <td>0.827539</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>32</td>\n",
       "      <td>Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?</td>\n",
       "      <td>ESDDVCIP, LCOTARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, OSCILLATE, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, CHEST, ESCPARDS, PROSEVA</td>\n",
       "      <td>0.841921</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>33</td>\n",
       "      <td>Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??</td>\n",
       "      <td>ESDDVCIP, MHNOCA</td>\n",
       "      <td>THvsTN, CETHACA</td>\n",
       "      <td>0.852407</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>34</td>\n",
       "      <td>Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?</td>\n",
       "      <td>BTCSCA</td>\n",
       "      <td>RIC, CAC, SEPSISPAM, OHCA, EXACT, MCAU, CETHACA, IHCA, BTCSCA, THvsTN</td>\n",
       "      <td>0.843637</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>35</td>\n",
       "      <td>Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?</td>\n",
       "      <td>OTCSCA, SPICE-III, HDDSICU, ESDDVCIP</td>\n",
       "      <td>RIC, CAC, HACA-LA, OHCA, EXACT, CETHACA, BTCSCA, THvsTN</td>\n",
       "      <td>0.843511</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?</td>\n",
       "      <td>ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVCIP, DPSMVAS, DIICU, RAEATICU, SPICE-III, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, EDvsLSMENDS, DDS, ETSDMV</td>\n",
       "      <td>0.850530</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Question Number  \\\n",
       "0                 1   \n",
       "1                 2   \n",
       "2                 3   \n",
       "3                 4   \n",
       "4                 5   \n",
       "5                 6   \n",
       "6                 7   \n",
       "7                 8   \n",
       "8                 9   \n",
       "9                10   \n",
       "10               11   \n",
       "11               12   \n",
       "12               13   \n",
       "13               14   \n",
       "14               15   \n",
       "15               16   \n",
       "16               17   \n",
       "17               18   \n",
       "18               19   \n",
       "19               20   \n",
       "20               21   \n",
       "21               22   \n",
       "22               23   \n",
       "23               24   \n",
       "24               25   \n",
       "25               26   \n",
       "26               27   \n",
       "27               28   \n",
       "28               29   \n",
       "29               30   \n",
       "30               31   \n",
       "31               32   \n",
       "32               33   \n",
       "33               34   \n",
       "34               35   \n",
       "35               36   \n",
       "\n",
       "                                                                                                                                                                                                                                     Question  \\\n",
       "0                                                                                                                                              Does early administration of neuromuscular blocking agents increases the ventilator free days?   \n",
       "1                                                                                                                               Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?   \n",
       "2                                                                                                                            In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?   \n",
       "3   Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who received an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?   \n",
       "4                                                                               Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?   \n",
       "5                                                                                                                       Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?   \n",
       "6                                                                                         Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?   \n",
       "7                                                                   Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?   \n",
       "8                                                                                                                                                  Prone positioning sessions in patients with severe ARDS significantly decreased mortality?   \n",
       "9                                                                                                 Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?   \n",
       "10                                                                                                  Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?   \n",
       "11                                               Does a 7-day treatment with low doses of steroids significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?   \n",
       "12                                                                                                         Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?   \n",
       "13                                                                                                                                                     Does steroids hasten the reversal of shock in patients whom had septic shock reversed?   \n",
       "14                                                                                                                                               Does early administration of acetaminophen to treat fever affect the number of ICU-free days   \n",
       "15                                                                                                                                     Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?   \n",
       "16                                                                                                                      Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival   \n",
       "17                                                                                                                              Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?   \n",
       "18                                                                                                                    Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?   \n",
       "19                                                                                           Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?   \n",
       "20                                                                            In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?   \n",
       "21                                 In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?   \n",
       "22              Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favorable neurologic outcome and reduce mortality?   \n",
       "23                                                      Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?   \n",
       "24                                                      Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?   \n",
       "25                                                                                                                                                           Is there more adverse events in ICU patients who recieved early dexmedetomidine?   \n",
       "26                                                                   Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?   \n",
       "27                                                                                                   Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?   \n",
       "28                                                                                                                                                     Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?   \n",
       "29                                                            At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?   \n",
       "30                                                                                                                              Does routine use of corticosteroids for persistent ARDS over prolonged periods have increased survival rate?    \n",
       "31                                                                                                                Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?   \n",
       "32                                                  Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??   \n",
       "33                                                                                                             Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?   \n",
       "34                                               Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?   \n",
       "35                                                                                                  Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?   \n",
       "\n",
       "                                                                                                                                                                            Docs  \\\n",
       "0                                                                                                ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS   \n",
       "1                                                                                        ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS   \n",
       "2                                                                                                                      ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS   \n",
       "3                                                                                                                      ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS   \n",
       "4                                                                                                                                   FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS   \n",
       "5                                                                                                                                   FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS   \n",
       "6                                                                                                                                  APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET   \n",
       "7                                                                                                              APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsARDSNET, DIHRFARDSNET   \n",
       "8                                                                                                                         ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, PPATDSHMA   \n",
       "9                                                                                                                       HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-ICU, SEDCOM   \n",
       "10                                                                        ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SEDCOM, APROCCHSS   \n",
       "11  ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, MIND-USA, NEvsVP, EDvsLSMENDS, ESDDVCIP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, APROCCHSS   \n",
       "12                                                                                                              ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS   \n",
       "13                                                                                                              ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS   \n",
       "14                                                                                                                                                                ESDDVCIP, HEAT   \n",
       "15                                                                                                                                      ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS   \n",
       "16                                                                                                                              RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS   \n",
       "17                                                                                                                                                                  SAFE, FRESHS   \n",
       "18                                                                                                                             RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial   \n",
       "19                                                                                                                                      ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS   \n",
       "20                                                                           MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA   \n",
       "21                                                                           MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA   \n",
       "22                                                            MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SRRCTTHNPCAP, HACA, ITMNCA, SOPA-III, HNPCASR, VMOCA, TCAIHCA, HACA-LA   \n",
       "23                                                                   ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, RDSCI, DDMLSMVICP   \n",
       "24                                                           ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SEDCOM, RDSCI, DDMLSMVICP   \n",
       "25                ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "26        ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, DDMLSMVICP   \n",
       "27                 ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "28                           ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "29                           ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "30                                                                                                                                                            ESDDVCIP, ESCPARDS   \n",
       "31                                                                                                                                                            ESDDVCIP, LCOTARDS   \n",
       "32                                                                                                                                                              ESDDVCIP, MHNOCA   \n",
       "33                                                                                                                                                                        BTCSCA   \n",
       "34                                                                                                                                          OTCSCA, SPICE-III, HDDSICU, ESDDVCIP   \n",
       "35                                                              ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVCIP, DPSMVAS, DIICU, RAEATICU, SPICE-III, SEDCOM, RDSCI, DDMLSMVICP   \n",
       "\n",
       "                                                                                                                                Retrieved Files  \\\n",
       "0                                                                  ENB, TOF-ARDS, ACURASYS, ESCNBC, FMWSCPARDS, SMDLTSWCI, DDS, HDDSICU, ETSDMV   \n",
       "1                                          ROSE, ACURASYS, ESCNBC, OSCILLATE, NBSARDS, CEIIUPPSARDS, PTARDS, PPATDSHMA, EDPMARDSLPMV, APV, LSPA   \n",
       "2            ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA   \n",
       "3                                                                         ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, CEIIUPPSARDS, NBSARDS, PPATDSHMA   \n",
       "4                                                                                                 RARDS, FMWSCPARDS, DIHRFARDSNET, PAC-in-FACTT   \n",
       "5                                                                                                         FACTT, FMWSCPARDS, RARDS, ARDSSRDRFMS   \n",
       "6                                                           HARDST, ENB, ARDSSRDRFMS, NBSARDS, CEIIUPPSARDS, RARDS, EDPMARDSLPMV, ARDSNet, LSPA   \n",
       "7                            HARDST, ENB, ARDSSRDRFMS, FMWSCPARDS, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV   \n",
       "8                                ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, FMWSCPARDS, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, APV, LSPA   \n",
       "9                            HARDST, ENB, OSCILLATE, BMIMSARDS, DDMLSMVICP, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV   \n",
       "10                                                            ANNANE, CORTICUS, ADRENAL, HYPRESS, TRISS, SS3vsSS2, APROCCHSS, PLMALDHSS, FRESHS   \n",
       "11                                                                                                         PLMALDHSS, ANNANE, ADRENAL, CORTICUS   \n",
       "12                                                                                     ANNANE, CORTICUS, ADRENAL, HYPRESS, APROCCHSS, PLMALDHSS   \n",
       "13                                             VASST, CORTICUS, ANNANE, ADRENAL, HYPRESS, SS3vsSS2, TRISS, NEvsVP, APROCCHSS, PLMALDHSS, FRESHS   \n",
       "14                                                                                                                                         HEAT   \n",
       "15                              PROWESS, ULS, EDIS, CABS, LOVIT, SADASS, ALBIOS, Rivers Trial, PROWESS-SHOCK, APROCCHSS, PLMALDHSS, EDvsLSMENDS   \n",
       "16                                                                                                                        ULS, ALBIOS, SS3vsSS2   \n",
       "17                                                                                                   SAFE, FEAST, SS3vsSS2, SADASS, ALBIOS, DDS   \n",
       "18                                                                                                                 Rivers Trial, ProCESS, ARISE   \n",
       "19                                                                                                             PROWESS-SHOCK, APROCCHSS, SADASS   \n",
       "20                                                                 RIC, HACA-LA, TCAIHCA, TTM2, CETHACA, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR   \n",
       "21                                                                                      RIC, HACA-LA, TCAIHCA, TTM2, HACA, TTM, THvsTN, HNPCASR   \n",
       "22                                                                 RIC, HACA-LA, TCAIHCA, CETHACA, TTM2, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR   \n",
       "23                                                                                                   DIICU, AID-ICU, RUSGATICUD, RAEATICU, AMTD   \n",
       "24                                                                                                   DIICU, AID-ICU, RUSGATICUD, AMTD, RAEATICU   \n",
       "25                                                                               SPICE-III, RDSCI, DDMLSMVICP, DIICU, ESDDVCIP, HDDSICU, ETSDMV   \n",
       "26                                                                        SPICE-III, RDSCI, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV   \n",
       "27                                                            SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV   \n",
       "28                                                              SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, SEDCOM, DDS, HDDSICU, ETSDMV   \n",
       "29                                                                                SPICE-III, RDSCI, ESDDVCIP, EDvsLSMENDS, DDS, HDDSICU, ETSDMV   \n",
       "30  HARDST, ROSE, TOF-ARDS, ACURASYS, CCCARDS, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA   \n",
       "31                         ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, OSCILLATE, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, CHEST, ESCPARDS, PROSEVA   \n",
       "32                                                                                                                              THvsTN, CETHACA   \n",
       "33                                                                        RIC, CAC, SEPSISPAM, OHCA, EXACT, MCAU, CETHACA, IHCA, BTCSCA, THvsTN   \n",
       "34                                                                                      RIC, CAC, HACA-LA, OHCA, EXACT, CETHACA, BTCSCA, THvsTN   \n",
       "35                                                                  SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, EDvsLSMENDS, DDS, ETSDMV   \n",
       "\n",
       "    Avg Similarity  \n",
       "0         0.822698  \n",
       "1         0.854614  \n",
       "2         0.847302  \n",
       "3         0.812959  \n",
       "4         0.817033  \n",
       "5         0.843431  \n",
       "6         0.875296  \n",
       "7         0.857474  \n",
       "8         0.853484  \n",
       "9         0.847682  \n",
       "10        0.869297  \n",
       "11        0.830495  \n",
       "12        0.819342  \n",
       "13        0.826625  \n",
       "14        0.887364  \n",
       "15        0.849581  \n",
       "16        0.873086  \n",
       "17        0.845052  \n",
       "18        0.812549  \n",
       "19        0.842357  \n",
       "20        0.891963  \n",
       "21        0.882604  \n",
       "22        0.879469  \n",
       "23        0.865217  \n",
       "24        0.815780  \n",
       "25        0.845843  \n",
       "26        0.892401  \n",
       "27        0.892393  \n",
       "28        0.840727  \n",
       "29        0.870136  \n",
       "30        0.827539  \n",
       "31        0.841921  \n",
       "32        0.852407  \n",
       "33        0.843637  \n",
       "34        0.843511  \n",
       "35        0.850530  "
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "concatenated_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define total_vocab as a set of all unique document identifiers\n",
    "total_vocab = spreadsheet.get_worksheet(1).col_values(3)[1:]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'ACURASYS',\n",
       " 'ADRENAL',\n",
       " 'AID-ICU',\n",
       " 'ALBIOS',\n",
       " 'AMTD',\n",
       " 'ANNANE',\n",
       " 'APROCCHSS',\n",
       " 'APV',\n",
       " 'ARDSNet',\n",
       " 'ARDSSRDRFMS',\n",
       " 'ARISE',\n",
       " 'ASD',\n",
       " 'ATD',\n",
       " 'AUDDICU',\n",
       " 'AUPTICUPP',\n",
       " 'BMIMSARDS',\n",
       " 'BTCSCA',\n",
       " 'CABS',\n",
       " 'CAC ',\n",
       " 'CCCARDS',\n",
       " 'CEIIUPPSARDS',\n",
       " 'CETHACA',\n",
       " 'CHEST',\n",
       " 'CORTICUS',\n",
       " 'DDMLSMVICP',\n",
       " 'DDS',\n",
       " 'DIHRFARDSNET',\n",
       " 'DIICU',\n",
       " 'DLASPEEPvsARDSNET',\n",
       " 'DPD',\n",
       " 'DPSMVAS',\n",
       " 'DTNP',\n",
       " 'EDIS',\n",
       " 'EDPMARDSLPMV',\n",
       " 'EDVARCA',\n",
       " 'EDvsLSMENDS',\n",
       " 'EHPSS',\n",
       " 'ENB',\n",
       " 'ESCNBC',\n",
       " 'ESCPARDS',\n",
       " 'ESDDVCIP',\n",
       " 'ETSDMV',\n",
       " 'EXACT',\n",
       " 'FACTT',\n",
       " 'FDSD ',\n",
       " 'FEAST',\n",
       " 'FMWSCPARDS',\n",
       " 'FRESHS',\n",
       " 'HACA',\n",
       " 'HACA-LA',\n",
       " 'HARDST',\n",
       " 'HDDSICU',\n",
       " 'HEAT',\n",
       " 'HNPCASR',\n",
       " 'HYPRESS',\n",
       " 'IDEAL-ICU',\n",
       " 'IHCA ',\n",
       " 'ITMNCA',\n",
       " 'LCOTARDS',\n",
       " 'LOVIT',\n",
       " 'LSPA',\n",
       " 'MCAU ',\n",
       " 'MHNOCA',\n",
       " 'MIND-USA',\n",
       " 'MPOHCAUSPITHRCA',\n",
       " 'NBSARDS',\n",
       " 'ND',\n",
       " 'NEvsVP',\n",
       " 'NSEPSIS',\n",
       " 'NSS',\n",
       " 'OHCA ',\n",
       " 'OSCILLATE',\n",
       " 'OTCSCA',\n",
       " 'PAC-in-FACTT',\n",
       " 'PDHP',\n",
       " 'PESDCOMV',\n",
       " 'PLMALDHSS',\n",
       " 'PPATDSHMA',\n",
       " 'PROSEVA',\n",
       " 'PROWESS',\n",
       " 'PROWESS-SHOCK',\n",
       " 'PTARDS',\n",
       " 'PVOEMVRARDS',\n",
       " 'ProCESS',\n",
       " 'ProMISe',\n",
       " 'RAEATICU',\n",
       " 'RARDS',\n",
       " 'RDSCI',\n",
       " 'RIC ',\n",
       " 'ROSE',\n",
       " 'RUSGATICUD',\n",
       " 'Rivers Trial',\n",
       " 'SADASS',\n",
       " 'SAFE',\n",
       " 'SEDCOM',\n",
       " 'SEPSISPAM',\n",
       " 'SMDLTSWCI',\n",
       " 'SOAP-II',\n",
       " 'SOPA III',\n",
       " 'SPICE-III',\n",
       " 'SRRCTTHNPCAP',\n",
       " 'SS3vsSS2',\n",
       " 'TCAIHCA',\n",
       " 'THvsTN',\n",
       " 'TOF-ARDS',\n",
       " 'TRISS',\n",
       " 'TTM',\n",
       " 'TTM2',\n",
       " 'UHSEPSIS',\n",
       " 'ULS',\n",
       " 'VASST',\n",
       " 'VMOCA'}"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "total_vocab_set = set(total_vocab)\n",
    "total_vocab_set"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question Number</th>\n",
       "      <th>Question</th>\n",
       "      <th>Docs</th>\n",
       "      <th>Retrieved Files</th>\n",
       "      <th>Avg Similarity</th>\n",
       "      <th>Accuracy</th>\n",
       "      <th>Precision</th>\n",
       "      <th>Recall</th>\n",
       "      <th>F1</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Does early administration of neuromuscular blocking agents increases the ventilator free days?</td>\n",
       "      <td>ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ENB, TOF-ARDS, ACURASYS, ESCNBC, FMWSCPARDS, SMDLTSWCI, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.822698</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>0.444444</td>\n",
       "      <td>0.444444</td>\n",
       "      <td>0.444444</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?</td>\n",
       "      <td>ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ROSE, ACURASYS, ESCNBC, OSCILLATE, NBSARDS, CEIIUPPSARDS, PTARDS, PPATDSHMA, EDPMARDSLPMV, APV, LSPA</td>\n",
       "      <td>0.854614</td>\n",
       "      <td>0.919643</td>\n",
       "      <td>0.545455</td>\n",
       "      <td>0.600000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA</td>\n",
       "      <td>0.847302</td>\n",
       "      <td>0.883929</td>\n",
       "      <td>0.285714</td>\n",
       "      <td>0.571429</td>\n",
       "      <td>0.380952</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who received an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, CEIIUPPSARDS, NBSARDS, PPATDSHMA</td>\n",
       "      <td>0.812959</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.428571</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "      <td>RARDS, FMWSCPARDS, DIHRFARDSNET, PAC-in-FACTT</td>\n",
       "      <td>0.817033</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "      <td>FACTT, FMWSCPARDS, RARDS, ARDSSRDRFMS</td>\n",
       "      <td>0.843431</td>\n",
       "      <td>0.982143</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.750000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "      <td>HARDST, ENB, ARDSSRDRFMS, NBSARDS, CEIIUPPSARDS, RARDS, EDPMARDSLPMV, ARDSNet, LSPA</td>\n",
       "      <td>0.875296</td>\n",
       "      <td>0.901786</td>\n",
       "      <td>0.111111</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.153846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?</td>\n",
       "      <td>APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "      <td>HARDST, ENB, ARDSSRDRFMS, FMWSCPARDS, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV</td>\n",
       "      <td>0.857474</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.083333</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.111111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Prone positioning sessions in patients with severe ARDS significantly decreased mortality?</td>\n",
       "      <td>ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, PPATDSHMA</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, FMWSCPARDS, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, APV, LSPA</td>\n",
       "      <td>0.853484</td>\n",
       "      <td>0.883929</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.235294</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?</td>\n",
       "      <td>HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-ICU, SEDCOM</td>\n",
       "      <td>HARDST, ENB, OSCILLATE, BMIMSARDS, DDMLSMVICP, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV</td>\n",
       "      <td>0.847682</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.083333</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.111111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?</td>\n",
       "      <td>ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SEDCOM, APROCCHSS</td>\n",
       "      <td>ANNANE, CORTICUS, ADRENAL, HYPRESS, TRISS, SS3vsSS2, APROCCHSS, PLMALDHSS, FRESHS</td>\n",
       "      <td>0.869297</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.545455</td>\n",
       "      <td>0.600000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Does a 7-day treatment with low doses of steroids significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?</td>\n",
       "      <td>ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, MIND-USA, NEvsVP, EDvsLSMENDS, ESDDVCIP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, APROCCHSS</td>\n",
       "      <td>PLMALDHSS, ANNANE, ADRENAL, CORTICUS</td>\n",
       "      <td>0.830495</td>\n",
       "      <td>0.875000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.222222</td>\n",
       "      <td>0.363636</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS</td>\n",
       "      <td>ANNANE, CORTICUS, ADRENAL, HYPRESS, APROCCHSS, PLMALDHSS</td>\n",
       "      <td>0.819342</td>\n",
       "      <td>0.991071</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.923077</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Does steroids hasten the reversal of shock in patients whom had septic shock reversed?</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS</td>\n",
       "      <td>VASST, CORTICUS, ANNANE, ADRENAL, HYPRESS, SS3vsSS2, TRISS, NEvsVP, APROCCHSS, PLMALDHSS, FRESHS</td>\n",
       "      <td>0.826625</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.636364</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.777778</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Does early administration of acetaminophen to treat fever affect the number of ICU-free days</td>\n",
       "      <td>ESDDVCIP, HEAT</td>\n",
       "      <td>HEAT</td>\n",
       "      <td>0.887364</td>\n",
       "      <td>0.991071</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "      <td>PROWESS, ULS, EDIS, CABS, LOVIT, SADASS, ALBIOS, Rivers Trial, PROWESS-SHOCK, APROCCHSS, PLMALDHSS, EDvsLSMENDS</td>\n",
       "      <td>0.849581</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.375000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival</td>\n",
       "      <td>RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS</td>\n",
       "      <td>ULS, ALBIOS, SS3vsSS2</td>\n",
       "      <td>0.873086</td>\n",
       "      <td>0.973214</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?</td>\n",
       "      <td>SAFE, FRESHS</td>\n",
       "      <td>SAFE, FEAST, SS3vsSS2, SADASS, ALBIOS, DDS</td>\n",
       "      <td>0.845052</td>\n",
       "      <td>0.946429</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.250000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?</td>\n",
       "      <td>RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial</td>\n",
       "      <td>Rivers Trial, ProCESS, ARISE</td>\n",
       "      <td>0.812549</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "      <td>PROWESS-SHOCK, APROCCHSS, SADASS</td>\n",
       "      <td>0.842357</td>\n",
       "      <td>0.973214</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, TTM2, CETHACA, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR</td>\n",
       "      <td>0.891963</td>\n",
       "      <td>0.946903</td>\n",
       "      <td>0.777778</td>\n",
       "      <td>0.636364</td>\n",
       "      <td>0.700000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, TTM2, HACA, TTM, THvsTN, HNPCASR</td>\n",
       "      <td>0.882604</td>\n",
       "      <td>0.938053</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.545455</td>\n",
       "      <td>0.631579</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favorable neurologic outcome and reduce mortality?</td>\n",
       "      <td>MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SRRCTTHNPCAP, HACA, ITMNCA, SOPA-III, HNPCASR, VMOCA, TCAIHCA, HACA-LA</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, CETHACA, TTM2, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR</td>\n",
       "      <td>0.879469</td>\n",
       "      <td>0.938596</td>\n",
       "      <td>0.777778</td>\n",
       "      <td>0.583333</td>\n",
       "      <td>0.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, RDSCI, DDMLSMVICP</td>\n",
       "      <td>DIICU, AID-ICU, RUSGATICUD, RAEATICU, AMTD</td>\n",
       "      <td>0.865217</td>\n",
       "      <td>0.937500</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.416667</td>\n",
       "      <td>0.588235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "      <td>DIICU, AID-ICU, RUSGATICUD, AMTD, RAEATICU</td>\n",
       "      <td>0.815780</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.384615</td>\n",
       "      <td>0.555556</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>Is there more adverse events in ICU patients who recieved early dexmedetomidine?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, DIICU, ESDDVCIP, HDDSICU, ETSDMV</td>\n",
       "      <td>0.845843</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>0.583333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.892401</td>\n",
       "      <td>0.892857</td>\n",
       "      <td>0.875000</td>\n",
       "      <td>0.388889</td>\n",
       "      <td>0.538462</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.892393</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>0.888889</td>\n",
       "      <td>0.470588</td>\n",
       "      <td>0.615385</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, SEDCOM, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.840727</td>\n",
       "      <td>0.919643</td>\n",
       "      <td>0.888889</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.640000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, ESDDVCIP, EDvsLSMENDS, DDS, HDDSICU, ETSDMV</td>\n",
       "      <td>0.870136</td>\n",
       "      <td>0.901786</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.375000</td>\n",
       "      <td>0.521739</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>31</td>\n",
       "      <td>Does routine use of corticosteroids for persistent ARDS over prolonged periods have increased survival rate?</td>\n",
       "      <td>ESDDVCIP, ESCPARDS</td>\n",
       "      <td>HARDST, ROSE, TOF-ARDS, ACURASYS, CCCARDS, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA</td>\n",
       "      <td>0.827539</td>\n",
       "      <td>0.866071</td>\n",
       "      <td>0.066667</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.117647</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>32</td>\n",
       "      <td>Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?</td>\n",
       "      <td>ESDDVCIP, LCOTARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, OSCILLATE, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, CHEST, ESCPARDS, PROSEVA</td>\n",
       "      <td>0.841921</td>\n",
       "      <td>0.875000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>33</td>\n",
       "      <td>Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??</td>\n",
       "      <td>ESDDVCIP, MHNOCA</td>\n",
       "      <td>THvsTN, CETHACA</td>\n",
       "      <td>0.852407</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>34</td>\n",
       "      <td>Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?</td>\n",
       "      <td>BTCSCA</td>\n",
       "      <td>RIC, CAC, SEPSISPAM, OHCA, EXACT, MCAU, CETHACA, IHCA, BTCSCA, THvsTN</td>\n",
       "      <td>0.843637</td>\n",
       "      <td>0.923077</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.181818</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>35</td>\n",
       "      <td>Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?</td>\n",
       "      <td>OTCSCA, SPICE-III, HDDSICU, ESDDVCIP</td>\n",
       "      <td>RIC, CAC, HACA-LA, OHCA, EXACT, CETHACA, BTCSCA, THvsTN</td>\n",
       "      <td>0.843511</td>\n",
       "      <td>0.895652</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?</td>\n",
       "      <td>ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVCIP, DPSMVAS, DIICU, RAEATICU, SPICE-III, SEDCOM, RDSCI, DDMLSMVICP</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, EDvsLSMENDS, DDS, ETSDMV</td>\n",
       "      <td>0.850530</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.600000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Question Number  \\\n",
       "0                 1   \n",
       "1                 2   \n",
       "2                 3   \n",
       "3                 4   \n",
       "4                 5   \n",
       "5                 6   \n",
       "6                 7   \n",
       "7                 8   \n",
       "8                 9   \n",
       "9                10   \n",
       "10               11   \n",
       "11               12   \n",
       "12               13   \n",
       "13               14   \n",
       "14               15   \n",
       "15               16   \n",
       "16               17   \n",
       "17               18   \n",
       "18               19   \n",
       "19               20   \n",
       "20               21   \n",
       "21               22   \n",
       "22               23   \n",
       "23               24   \n",
       "24               25   \n",
       "25               26   \n",
       "26               27   \n",
       "27               28   \n",
       "28               29   \n",
       "29               30   \n",
       "30               31   \n",
       "31               32   \n",
       "32               33   \n",
       "33               34   \n",
       "34               35   \n",
       "35               36   \n",
       "\n",
       "                                                                                                                                                                                                                                     Question  \\\n",
       "0                                                                                                                                              Does early administration of neuromuscular blocking agents increases the ventilator free days?   \n",
       "1                                                                                                                               Do patients with severe ARDS being treated with neuromuscular blocking agents have increased muscle weakness?   \n",
       "2                                                                                                                            In patients with moderate to severe ARDS, does early use of continuous neuromuscular blockade improve mortality?   \n",
       "3   Do patients with moderate-to-severe ARDS have a significance difference in mortality rate between patients who received an early and continuous cisatracurium infusion than those with usual care approach with lighter sedation targets?   \n",
       "4                                                                               Among patients with ALI/ARDS, does a conservative fluid management strategy improves lung function and decrease ventilator days compared to liberal strategy?   \n",
       "5                                                                                                                       Does a conservative fluid management strategy result in a significant difference in mortality as the primary outcome?   \n",
       "6                                                                                         Does mechanical ventilation with a lower tidal volume result in decreased mortality with acute lung injury and acute respiratory distress syndrome?   \n",
       "7                                                                   Does mechanical ventilation with a lower tidal volume result increased ventilator free days with patients with acute lung injury and acute respiratory distress syndrome?   \n",
       "8                                                                                                                                                  Prone positioning sessions in patients with severe ARDS significantly decreased mortality?   \n",
       "9                                                                                                 Does early application of high frequency oscillatory ventilation compared with ventilation strategy of low tidal volume decrease mortality?   \n",
       "10                                                                                                  Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?   \n",
       "11                                               Does a 7-day treatment with low doses of steroids significantly reduce the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events?   \n",
       "12                                                                                                         Do patients who receive hydrocortisone plus fludrocortisone have a lower 90-day all cause mortality than patients given a placebo?   \n",
       "13                                                                                                                                                     Does steroids hasten the reversal of shock in patients whom had septic shock reversed?   \n",
       "14                                                                                                                                               Does early administration of acetaminophen to treat fever affect the number of ICU-free days   \n",
       "15                                                                                                                                     Does treatment with activated C protein significantly reduce mortality in patients with severe sepsis?   \n",
       "16                                                                                                                      Albumin replacement in addition to crystalloids compared with crystalloids alone did not improve the rate of survival   \n",
       "17                                                                                                                              Does the use albumin for fluid resuscitation result in similar outcome at 28 days with that of normal saline?   \n",
       "18                                                                                                                    Did hemodynamic management according to a strict early goal directed therapy protocol led to an improvement in outcome?   \n",
       "19                                                                                           Does treatment with DrotAA (activated) significantly reduce mortality at 28 days or 90 days compared with placebo in patients with septic shock?   \n",
       "20                                                                            In patients with coma after out-of-hospital cardiac arrest, did targeted hypothermia lead to a lower incidence of death by 6 months than targeted normothermia?   \n",
       "21                                 In unconscious survivors of out-of-hospital cardiac arrest of presumed cardiac cause, does hypothermia at a targeted temperature of 33Â°C provide any benefit compared with a targeted temperature of 36Â°C?   \n",
       "22              Following patients that have been fully resuscitated after cardiac arrest secondary to a ventricular fibrillation, did therapeutic mild hypothermia increase the rate of a favorable neurologic outcome and reduce mortality?   \n",
       "23                                                      Does treatment with haloperidol lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo when encountering patients in ICU with delirium?   \n",
       "24                                                      Does the use of ziprasidone as compared with placebo in patients with acute respiratory failure, shock, hypoactive or hyperactive delirium in the ICU alter the duration of delirium?   \n",
       "25                                                                                                                                                           Is there more adverse events in ICU patients who recieved early dexmedetomidine?   \n",
       "26                                                                   Among patients undergoing mechanical ventilation in the ICU, does early dexmedetomidine for sedation result in a mortality rate similar to that of the usual-care group?   \n",
       "27                                                                                                   Was there a difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients?   \n",
       "28                                                                                                                                                     Is bradycardia an adverse effect in critically ill patients receiving dexmedetomidine?   \n",
       "29                                                            At comparable sedation levels, did dexmedetomidine-treated patients spend less time on the ventilator, experience less delirium, and develop less tachycardia and hypertension?   \n",
       "30                                                                                                                              Does routine use of corticosteroids for persistent ARDS over prolonged periods have increased survival rate?    \n",
       "31                                                                                                                Is there a decrease in mortality rate among patients with ARDS with an early exposure to conservative oxygenation strategy?   \n",
       "32                                                  Is there a better neurologic outcome between targeted mild hypercapnia than targeted normocapnia in patients with a coma who were resuscitated following out of hospital cardiac arrest??   \n",
       "33                                                                                                             Does targeting a mean arterial blood pressure of 63 or 77 mm Hg in patients resuscitated from cardiac arrest reduce mortality?   \n",
       "34                                               Does targeting a restrictive or liberal oxygenation strategy in comatose patients after resuscitation for cardiac arrest result in a similar incidence of death, severe disability, or coma?   \n",
       "35                                                                                                  Is there a difference in outcomes in patients who receive dexmedetomidine than propofol among mechanically ventilated adults with sepsis?   \n",
       "\n",
       "                                                                                                                                                                            Docs  \\\n",
       "0                                                                                                ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS   \n",
       "1                                                                                        ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, EDPMARDSLPMV, PVOEMVRARDS, TOF-ARDS   \n",
       "2                                                                                                                      ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS   \n",
       "3                                                                                                                      ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARDS, TOF-ARDS   \n",
       "4                                                                                                                                   FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS   \n",
       "5                                                                                                                                   FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS   \n",
       "6                                                                                                                                  APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET   \n",
       "7                                                                                                              APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsARDSNET, DIHRFARDSNET   \n",
       "8                                                                                                                         ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, PPATDSHMA   \n",
       "9                                                                                                                       HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-ICU, SEDCOM   \n",
       "10                                                                        ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SEDCOM, APROCCHSS   \n",
       "11  ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, MIND-USA, NEvsVP, EDvsLSMENDS, ESDDVCIP, HYPRESS, SPICE-III, PLMALDHSS, CORTICUS, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, APROCCHSS   \n",
       "12                                                                                                              ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS   \n",
       "13                                                                                                              ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS, NEvsVP, APROCCHSS   \n",
       "14                                                                                                                                                                ESDDVCIP, HEAT   \n",
       "15                                                                                                                                      ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS   \n",
       "16                                                                                                                              RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS   \n",
       "17                                                                                                                                                                  SAFE, FRESHS   \n",
       "18                                                                                                                             RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial   \n",
       "19                                                                                                                                      ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS   \n",
       "20                                                                           MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA   \n",
       "21                                                                           MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP, TTM, TTM2, ITMNCA, HNPCASR, VMOCA, TCAIHCA, HACA-LA   \n",
       "22                                                            MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SRRCTTHNPCAP, HACA, ITMNCA, SOPA-III, HNPCASR, VMOCA, TCAIHCA, HACA-LA   \n",
       "23                                                                   ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, RDSCI, DDMLSMVICP   \n",
       "24                                                           ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SEDCOM, RDSCI, DDMLSMVICP   \n",
       "25                ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "26        ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, AID-ICU, SMDLTSWCI, SEDCOM, RDSCI, DDMLSMVICP   \n",
       "27                 ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, RUSGATICUD, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "28                           ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "29                           ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUPTICUPP, EDvsLSMENDS, ESDDVCIP, AMTD, DIICU, RAEATICU, SPICE-III, SEDCOM, SMDLTSWCI, RDSCI, DDMLSMVICP   \n",
       "30                                                                                                                                                            ESDDVCIP, ESCPARDS   \n",
       "31                                                                                                                                                            ESDDVCIP, LCOTARDS   \n",
       "32                                                                                                                                                              ESDDVCIP, MHNOCA   \n",
       "33                                                                                                                                                                        BTCSCA   \n",
       "34                                                                                                                                          OTCSCA, SPICE-III, HDDSICU, ESDDVCIP   \n",
       "35                                                              ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVCIP, DPSMVAS, DIICU, RAEATICU, SPICE-III, SEDCOM, RDSCI, DDMLSMVICP   \n",
       "\n",
       "                                                                                                                                Retrieved Files  \\\n",
       "0                                                                  ENB, TOF-ARDS, ACURASYS, ESCNBC, FMWSCPARDS, SMDLTSWCI, DDS, HDDSICU, ETSDMV   \n",
       "1                                          ROSE, ACURASYS, ESCNBC, OSCILLATE, NBSARDS, CEIIUPPSARDS, PTARDS, PPATDSHMA, EDPMARDSLPMV, APV, LSPA   \n",
       "2            ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA   \n",
       "3                                                                         ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, CEIIUPPSARDS, NBSARDS, PPATDSHMA   \n",
       "4                                                                                                 RARDS, FMWSCPARDS, DIHRFARDSNET, PAC-in-FACTT   \n",
       "5                                                                                                         FACTT, FMWSCPARDS, RARDS, ARDSSRDRFMS   \n",
       "6                                                           HARDST, ENB, ARDSSRDRFMS, NBSARDS, CEIIUPPSARDS, RARDS, EDPMARDSLPMV, ARDSNet, LSPA   \n",
       "7                            HARDST, ENB, ARDSSRDRFMS, FMWSCPARDS, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV   \n",
       "8                                ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, FMWSCPARDS, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, APV, LSPA   \n",
       "9                            HARDST, ENB, OSCILLATE, BMIMSARDS, DDMLSMVICP, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, ARDSNet, LSPA, ETSDMV   \n",
       "10                                                            ANNANE, CORTICUS, ADRENAL, HYPRESS, TRISS, SS3vsSS2, APROCCHSS, PLMALDHSS, FRESHS   \n",
       "11                                                                                                         PLMALDHSS, ANNANE, ADRENAL, CORTICUS   \n",
       "12                                                                                     ANNANE, CORTICUS, ADRENAL, HYPRESS, APROCCHSS, PLMALDHSS   \n",
       "13                                             VASST, CORTICUS, ANNANE, ADRENAL, HYPRESS, SS3vsSS2, TRISS, NEvsVP, APROCCHSS, PLMALDHSS, FRESHS   \n",
       "14                                                                                                                                         HEAT   \n",
       "15                              PROWESS, ULS, EDIS, CABS, LOVIT, SADASS, ALBIOS, Rivers Trial, PROWESS-SHOCK, APROCCHSS, PLMALDHSS, EDvsLSMENDS   \n",
       "16                                                                                                                        ULS, ALBIOS, SS3vsSS2   \n",
       "17                                                                                                   SAFE, FEAST, SS3vsSS2, SADASS, ALBIOS, DDS   \n",
       "18                                                                                                                 Rivers Trial, ProCESS, ARISE   \n",
       "19                                                                                                             PROWESS-SHOCK, APROCCHSS, SADASS   \n",
       "20                                                                 RIC, HACA-LA, TCAIHCA, TTM2, CETHACA, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR   \n",
       "21                                                                                      RIC, HACA-LA, TCAIHCA, TTM2, HACA, TTM, THvsTN, HNPCASR   \n",
       "22                                                                 RIC, HACA-LA, TCAIHCA, CETHACA, TTM2, HACA, MPOHCAUSPITHRCA, THvsTN, HNPCASR   \n",
       "23                                                                                                   DIICU, AID-ICU, RUSGATICUD, RAEATICU, AMTD   \n",
       "24                                                                                                   DIICU, AID-ICU, RUSGATICUD, AMTD, RAEATICU   \n",
       "25                                                                               SPICE-III, RDSCI, DDMLSMVICP, DIICU, ESDDVCIP, HDDSICU, ETSDMV   \n",
       "26                                                                        SPICE-III, RDSCI, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV   \n",
       "27                                                            SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SEDCOM, EDvsLSMENDS, DDS, HDDSICU, ETSDMV   \n",
       "28                                                              SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, SEDCOM, DDS, HDDSICU, ETSDMV   \n",
       "29                                                                                SPICE-III, RDSCI, ESDDVCIP, EDvsLSMENDS, DDS, HDDSICU, ETSDMV   \n",
       "30  HARDST, ROSE, TOF-ARDS, ACURASYS, CCCARDS, BMIMSARDS, OSCILLATE, NBSARDS, CEIIUPPSARDS, PPATDSHMA, RARDS, EDPMARDSLPMV, APV, ESCPARDS, LSPA   \n",
       "31                         ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, OSCILLATE, CEIIUPPSARDS, NBSARDS, RARDS, EDPMARDSLPMV, CHEST, ESCPARDS, PROSEVA   \n",
       "32                                                                                                                              THvsTN, CETHACA   \n",
       "33                                                                        RIC, CAC, SEPSISPAM, OHCA, EXACT, MCAU, CETHACA, IHCA, BTCSCA, THvsTN   \n",
       "34                                                                                      RIC, CAC, HACA-LA, OHCA, EXACT, CETHACA, BTCSCA, THvsTN   \n",
       "35                                                                  SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTSWCI, EDvsLSMENDS, DDS, ETSDMV   \n",
       "\n",
       "    Avg Similarity  Accuracy  Precision    Recall        F1  \n",
       "0         0.822698  0.910714   0.444444  0.444444  0.444444  \n",
       "1         0.854614  0.919643   0.545455  0.600000  0.571429  \n",
       "2         0.847302  0.883929   0.285714  0.571429  0.380952  \n",
       "3         0.812959  0.928571   0.428571  0.428571  0.428571  \n",
       "4         0.817033  0.964286   0.500000  0.500000  0.500000  \n",
       "5         0.843431  0.982143   0.750000  0.750000  0.750000  \n",
       "6         0.875296  0.901786   0.111111  0.250000  0.153846  \n",
       "7         0.857474  0.857143   0.083333  0.166667  0.111111  \n",
       "8         0.853484  0.883929   0.166667  0.400000  0.235294  \n",
       "9         0.847682  0.857143   0.083333  0.166667  0.111111  \n",
       "10        0.869297  0.928571   0.666667  0.545455  0.600000  \n",
       "11        0.830495  0.875000   1.000000  0.222222  0.363636  \n",
       "12        0.819342  0.991071   1.000000  0.857143  0.923077  \n",
       "13        0.826625  0.964286   0.636364  1.000000  0.777778  \n",
       "14        0.887364  0.991071   1.000000  0.500000  0.666667  \n",
       "15        0.849581  0.910714   0.250000  0.750000  0.375000  \n",
       "16        0.873086  0.973214   1.000000  0.500000  0.666667  \n",
       "17        0.845052  0.946429   0.166667  0.500000  0.250000  \n",
       "18        0.812549  0.964286   0.666667  0.400000  0.500000  \n",
       "19        0.842357  0.973214   0.666667  0.500000  0.571429  \n",
       "20        0.891963  0.946903   0.777778  0.636364  0.700000  \n",
       "21        0.882604  0.938053   0.750000  0.545455  0.631579  \n",
       "22        0.879469  0.938596   0.777778  0.583333  0.666667  \n",
       "23        0.865217  0.937500   1.000000  0.416667  0.588235  \n",
       "24        0.815780  0.928571   1.000000  0.384615  0.555556  \n",
       "25        0.845843  0.910714   1.000000  0.411765  0.583333  \n",
       "26        0.892401  0.892857   0.875000  0.388889  0.538462  \n",
       "27        0.892393  0.910714   0.888889  0.470588  0.615385  \n",
       "28        0.840727  0.919643   0.888889  0.500000  0.640000  \n",
       "29        0.870136  0.901786   0.857143  0.375000  0.521739  \n",
       "30        0.827539  0.866071   0.066667  0.500000  0.117647  \n",
       "31        0.841921  0.875000   0.000000  0.000000  0.000000  \n",
       "32        0.852407  0.964286   0.000000  0.000000  0.000000  \n",
       "33        0.843637  0.923077   0.100000  1.000000  0.181818  \n",
       "34        0.843511  0.895652   0.000000  0.000000  0.000000  \n",
       "35        0.850530  0.928571   0.750000  0.500000  0.600000  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Apply the function with total_vocab\n",
    "BM_df = apply_metrics(concatenated_df, total_vocab_set)\n",
    "\n",
    "# Display the updated DataFrame\n",
    "display(BM_df.head(36))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "BM_df.to_csv(\"./outputs/retrieved_final_1.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "BM_df = pd.read_csv(\"./outputs/retrieved_final_1.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Question Number</th>\n",
       "      <th>Question</th>\n",
       "      <th>Docs</th>\n",
       "      <th>Retrieved Files</th>\n",
       "      <th>Avg Similarity</th>\n",
       "      <th>Accuracy</th>\n",
       "      <th>Precision</th>\n",
       "      <th>Recall</th>\n",
       "      <th>F1</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Does early administration of neuromuscular blo...</td>\n",
       "      <td>ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, ED...</td>\n",
       "      <td>ENB, TOF-ARDS, ACURASYS, ESCNBC, FMWSCPARDS, S...</td>\n",
       "      <td>0.822698</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>0.444444</td>\n",
       "      <td>0.444444</td>\n",
       "      <td>0.444444</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Do patients with severe ARDS being treated wit...</td>\n",
       "      <td>ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ES...</td>\n",
       "      <td>ROSE, ACURASYS, ESCNBC, OSCILLATE, NBSARDS, CE...</td>\n",
       "      <td>0.854614</td>\n",
       "      <td>0.919643</td>\n",
       "      <td>0.545455</td>\n",
       "      <td>0.600000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>In patients with moderate to severe ARDS, does...</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARD...</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, O...</td>\n",
       "      <td>0.847302</td>\n",
       "      <td>0.883929</td>\n",
       "      <td>0.285714</td>\n",
       "      <td>0.571429</td>\n",
       "      <td>0.380952</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have ...</td>\n",
       "      <td>ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARD...</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, CEIIUPPSA...</td>\n",
       "      <td>0.812959</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.428571</td>\n",
       "      <td>0.428571</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservat...</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "      <td>RARDS, FMWSCPARDS, DIHRFARDSNET, PAC-in-FACTT</td>\n",
       "      <td>0.817033</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Does a conservative fluid management strategy ...</td>\n",
       "      <td>FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS</td>\n",
       "      <td>FACTT, FMWSCPARDS, RARDS, ARDSSRDRFMS</td>\n",
       "      <td>0.843431</td>\n",
       "      <td>0.982143</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.750000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal...</td>\n",
       "      <td>APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET</td>\n",
       "      <td>HARDST, ENB, ARDSSRDRFMS, NBSARDS, CEIIUPPSARD...</td>\n",
       "      <td>0.875296</td>\n",
       "      <td>0.901786</td>\n",
       "      <td>0.111111</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.153846</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>Does mechanical ventilation with a lower tidal...</td>\n",
       "      <td>APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsAR...</td>\n",
       "      <td>HARDST, ENB, ARDSSRDRFMS, FMWSCPARDS, NBSARDS,...</td>\n",
       "      <td>0.857474</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.083333</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.111111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>Prone positioning sessions in patients with se...</td>\n",
       "      <td>ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, P...</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, F...</td>\n",
       "      <td>0.853484</td>\n",
       "      <td>0.883929</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.235294</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>Does early application of high frequency oscil...</td>\n",
       "      <td>HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-I...</td>\n",
       "      <td>HARDST, ENB, OSCILLATE, BMIMSARDS, DDMLSMVICP,...</td>\n",
       "      <td>0.847682</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.083333</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.111111</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>Patients with septic shock undergoing mechanic...</td>\n",
       "      <td>ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SP...</td>\n",
       "      <td>ANNANE, CORTICUS, ADRENAL, HYPRESS, TRISS, SS3...</td>\n",
       "      <td>0.869297</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.545455</td>\n",
       "      <td>0.600000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>Does a 7-day treatment with low doses of stero...</td>\n",
       "      <td>ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, ...</td>\n",
       "      <td>PLMALDHSS, ANNANE, ADRENAL, CORTICUS</td>\n",
       "      <td>0.830495</td>\n",
       "      <td>0.875000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.222222</td>\n",
       "      <td>0.363636</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>Do patients who receive hydrocortisone plus fl...</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS,...</td>\n",
       "      <td>ANNANE, CORTICUS, ADRENAL, HYPRESS, APROCCHSS,...</td>\n",
       "      <td>0.819342</td>\n",
       "      <td>0.991071</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.923077</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>Does steroids hasten the reversal of shock in ...</td>\n",
       "      <td>ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS,...</td>\n",
       "      <td>VASST, CORTICUS, ANNANE, ADRENAL, HYPRESS, SS3...</td>\n",
       "      <td>0.826625</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.636364</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.777778</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>Does early administration of acetaminophen to ...</td>\n",
       "      <td>ESDDVCIP, HEAT</td>\n",
       "      <td>HEAT</td>\n",
       "      <td>0.887364</td>\n",
       "      <td>0.991071</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>Does treatment with activated C protein signif...</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "      <td>PROWESS, ULS, EDIS, CABS, LOVIT, SADASS, ALBIO...</td>\n",
       "      <td>0.849581</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>0.250000</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.375000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>Albumin replacement in addition to crystalloid...</td>\n",
       "      <td>RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS</td>\n",
       "      <td>ULS, ALBIOS, SS3vsSS2</td>\n",
       "      <td>0.873086</td>\n",
       "      <td>0.973214</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>Does the use albumin for fluid resuscitation r...</td>\n",
       "      <td>SAFE, FRESHS</td>\n",
       "      <td>SAFE, FEAST, SS3vsSS2, SADASS, ALBIOS, DDS</td>\n",
       "      <td>0.845052</td>\n",
       "      <td>0.946429</td>\n",
       "      <td>0.166667</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.250000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>Did hemodynamic management according to a stri...</td>\n",
       "      <td>RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial</td>\n",
       "      <td>Rivers Trial, ProCESS, ARISE</td>\n",
       "      <td>0.812549</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>0.500000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>Does treatment with DrotAA (activated) signifi...</td>\n",
       "      <td>ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS</td>\n",
       "      <td>PROWESS-SHOCK, APROCCHSS, SADASS</td>\n",
       "      <td>0.842357</td>\n",
       "      <td>0.973214</td>\n",
       "      <td>0.666667</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.571429</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>In patients with coma after out-of-hospital ca...</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP...</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, TTM2, CETHACA, HACA, MP...</td>\n",
       "      <td>0.891963</td>\n",
       "      <td>0.946903</td>\n",
       "      <td>0.777778</td>\n",
       "      <td>0.636364</td>\n",
       "      <td>0.700000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>In unconscious survivors of out-of-hospital ca...</td>\n",
       "      <td>MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP...</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, TTM2, HACA, TTM, THvsTN...</td>\n",
       "      <td>0.882604</td>\n",
       "      <td>0.938053</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.545455</td>\n",
       "      <td>0.631579</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>Following patients that have been fully resusc...</td>\n",
       "      <td>MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SR...</td>\n",
       "      <td>RIC, HACA-LA, TCAIHCA, CETHACA, TTM2, HACA, MP...</td>\n",
       "      <td>0.879469</td>\n",
       "      <td>0.938596</td>\n",
       "      <td>0.777778</td>\n",
       "      <td>0.583333</td>\n",
       "      <td>0.666667</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>Does treatment with haloperidol lead to a sign...</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP,...</td>\n",
       "      <td>DIICU, AID-ICU, RUSGATICUD, RAEATICU, AMTD</td>\n",
       "      <td>0.865217</td>\n",
       "      <td>0.937500</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.416667</td>\n",
       "      <td>0.588235</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>Does the use of ziprasidone as compared with p...</td>\n",
       "      <td>ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP,...</td>\n",
       "      <td>DIICU, AID-ICU, RUSGATICUD, AMTD, RAEATICU</td>\n",
       "      <td>0.815780</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.384615</td>\n",
       "      <td>0.555556</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>Is there more adverse events in ICU patients w...</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTI...</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, DIICU, ESDDVCIP,...</td>\n",
       "      <td>0.845843</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.411765</td>\n",
       "      <td>0.583333</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>Among patients undergoing mechanical ventilati...</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTI...</td>\n",
       "      <td>SPICE-III, RDSCI, ESDDVCIP, SEDCOM, EDvsLSMEND...</td>\n",
       "      <td>0.892401</td>\n",
       "      <td>0.892857</td>\n",
       "      <td>0.875000</td>\n",
       "      <td>0.388889</td>\n",
       "      <td>0.538462</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>Was there a difference between dexmedetomidine...</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTI...</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SEDCOM...</td>\n",
       "      <td>0.892393</td>\n",
       "      <td>0.910714</td>\n",
       "      <td>0.888889</td>\n",
       "      <td>0.470588</td>\n",
       "      <td>0.615385</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>Is bradycardia an adverse effect in critically...</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUP...</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTS...</td>\n",
       "      <td>0.840727</td>\n",
       "      <td>0.919643</td>\n",
       "      <td>0.888889</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.640000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>At comparable sedation levels, did dexmedetomi...</td>\n",
       "      <td>ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUP...</td>\n",
       "      <td>SPICE-III, RDSCI, ESDDVCIP, EDvsLSMENDS, DDS, ...</td>\n",
       "      <td>0.870136</td>\n",
       "      <td>0.901786</td>\n",
       "      <td>0.857143</td>\n",
       "      <td>0.375000</td>\n",
       "      <td>0.521739</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>31</td>\n",
       "      <td>Does routine use of corticosteroids for persis...</td>\n",
       "      <td>ESDDVCIP, ESCPARDS</td>\n",
       "      <td>HARDST, ROSE, TOF-ARDS, ACURASYS, CCCARDS, BMI...</td>\n",
       "      <td>0.827539</td>\n",
       "      <td>0.866071</td>\n",
       "      <td>0.066667</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.117647</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>32</td>\n",
       "      <td>Is there a decrease in mortality rate among pa...</td>\n",
       "      <td>ESDDVCIP, LCOTARDS</td>\n",
       "      <td>ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, OSCILLATE...</td>\n",
       "      <td>0.841921</td>\n",
       "      <td>0.875000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>33</td>\n",
       "      <td>Is there a better neurologic outcome between t...</td>\n",
       "      <td>ESDDVCIP, MHNOCA</td>\n",
       "      <td>THvsTN, CETHACA</td>\n",
       "      <td>0.852407</td>\n",
       "      <td>0.964286</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>34</td>\n",
       "      <td>Does targeting a mean arterial blood pressure ...</td>\n",
       "      <td>BTCSCA</td>\n",
       "      <td>RIC, CAC, SEPSISPAM, OHCA, EXACT, MCAU, CETHAC...</td>\n",
       "      <td>0.843637</td>\n",
       "      <td>0.923077</td>\n",
       "      <td>0.100000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.181818</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>35</td>\n",
       "      <td>Does targeting a restrictive or liberal oxygen...</td>\n",
       "      <td>OTCSCA, SPICE-III, HDDSICU, ESDDVCIP</td>\n",
       "      <td>RIC, CAC, HACA-LA, OHCA, EXACT, CETHACA, BTCSC...</td>\n",
       "      <td>0.843511</td>\n",
       "      <td>0.895652</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>Is there a difference in outcomes in patients ...</td>\n",
       "      <td>ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVC...</td>\n",
       "      <td>SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTS...</td>\n",
       "      <td>0.850530</td>\n",
       "      <td>0.928571</td>\n",
       "      <td>0.750000</td>\n",
       "      <td>0.500000</td>\n",
       "      <td>0.600000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    Question Number                                           Question  \\\n",
       "0                 1  Does early administration of neuromuscular blo...   \n",
       "1                 2  Do patients with severe ARDS being treated wit...   \n",
       "2                 3  In patients with moderate to severe ARDS, does...   \n",
       "3                 4  Do patients with moderate-to-severe ARDS have ...   \n",
       "4                 5  Among patients with ALI/ARDS, does a conservat...   \n",
       "5                 6  Does a conservative fluid management strategy ...   \n",
       "6                 7  Does mechanical ventilation with a lower tidal...   \n",
       "7                 8  Does mechanical ventilation with a lower tidal...   \n",
       "8                 9  Prone positioning sessions in patients with se...   \n",
       "9                10  Does early application of high frequency oscil...   \n",
       "10               11  Patients with septic shock undergoing mechanic...   \n",
       "11               12  Does a 7-day treatment with low doses of stero...   \n",
       "12               13  Do patients who receive hydrocortisone plus fl...   \n",
       "13               14  Does steroids hasten the reversal of shock in ...   \n",
       "14               15  Does early administration of acetaminophen to ...   \n",
       "15               16  Does treatment with activated C protein signif...   \n",
       "16               17  Albumin replacement in addition to crystalloid...   \n",
       "17               18  Does the use albumin for fluid resuscitation r...   \n",
       "18               19  Did hemodynamic management according to a stri...   \n",
       "19               20  Does treatment with DrotAA (activated) signifi...   \n",
       "20               21  In patients with coma after out-of-hospital ca...   \n",
       "21               22  In unconscious survivors of out-of-hospital ca...   \n",
       "22               23  Following patients that have been fully resusc...   \n",
       "23               24  Does treatment with haloperidol lead to a sign...   \n",
       "24               25  Does the use of ziprasidone as compared with p...   \n",
       "25               26  Is there more adverse events in ICU patients w...   \n",
       "26               27  Among patients undergoing mechanical ventilati...   \n",
       "27               28  Was there a difference between dexmedetomidine...   \n",
       "28               29  Is bradycardia an adverse effect in critically...   \n",
       "29               30  At comparable sedation levels, did dexmedetomi...   \n",
       "30               31  Does routine use of corticosteroids for persis...   \n",
       "31               32  Is there a decrease in mortality rate among pa...   \n",
       "32               33  Is there a better neurologic outcome between t...   \n",
       "33               34  Does targeting a mean arterial blood pressure ...   \n",
       "34               35  Does targeting a restrictive or liberal oxygen...   \n",
       "35               36  Is there a difference in outcomes in patients ...   \n",
       "\n",
       "                                                 Docs  \\\n",
       "0   ENB, LSPA, NBSARDS, ACURASYS, ROSE, ESCNBC, ED...   \n",
       "1   ETSDMV, ENB, LSPA, NBSARDS, ACURASYS, ROSE, ES...   \n",
       "2   ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARD...   \n",
       "3   ETSDMV, ENB, NBSARDS, ROSE, ESCNBC, PVOEMVRARD...   \n",
       "4        FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS   \n",
       "5        FMWSCPARDS, FACTT, PAC-in-FACTT, ARDSSRDRFMS   \n",
       "6       APV, ARDSNet, DLASPEEPvsARDSNET, DIHRFARDSNET   \n",
       "7   APV, ARDSNet, SPICE-III, AID-ICU, DLASPEEPvsAR...   \n",
       "8   ETSDMV, PROSEVA, CEIIUPPSARDS, EDPMARDSLPMV, P...   \n",
       "9   HDDSICU, MIND-USA, OSCILLATE, SPICE-III, AID-I...   \n",
       "10  ANNANE, ADRENAL, MIND-USA, NEvsVP, HYPRESS, SP...   \n",
       "11  ANNANE, ADRENAL, ETSDMV, DDMLSMVICP, HDDSICU, ...   \n",
       "12  ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS,...   \n",
       "13  ANNANE, ADRENAL, HYPRESS, PLMALDHSS, CORTICUS,...   \n",
       "14                                     ESDDVCIP, HEAT   \n",
       "15           ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS   \n",
       "16   RUSGATICUD, FRESHS, ULS, SS3vsSS2, ALBIOS, EHPSS   \n",
       "17                                       SAFE, FRESHS   \n",
       "18  RUSGATICUD, ProMISe, ARISE, AID-ICU, Rivers Trial   \n",
       "19           ESDDVCIP, SADASS, PROWESS-SHOCK, PROWESS   \n",
       "20  MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP...   \n",
       "21  MPOHCAUSPITHRCA, CETHACA, THvsTN, SRRCTTHNPCAP...   \n",
       "22  MPOHCAUSPITHRCA, ESDDVCIP, CETHACA, THvsTN, SR...   \n",
       "23  ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP,...   \n",
       "24  ATD, RUSGATICUD, MIND-USA, AUDDICU, AUPTICUPP,...   \n",
       "25  ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTI...   \n",
       "26  ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTI...   \n",
       "27  ETSDMV, ATD, HDDSICU, MIND-USA, AUDDICU, AUPTI...   \n",
       "28  ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUP...   \n",
       "29  ETSDMV, ATD, HDDSICU, RUSGATICUD, AUDDICU, AUP...   \n",
       "30                                 ESDDVCIP, ESCPARDS   \n",
       "31                                 ESDDVCIP, LCOTARDS   \n",
       "32                                   ESDDVCIP, MHNOCA   \n",
       "33                                             BTCSCA   \n",
       "34               OTCSCA, SPICE-III, HDDSICU, ESDDVCIP   \n",
       "35  ETSDMV, HDDSICU, MIND-USA, EDvsLSMENDS, ESDDVC...   \n",
       "\n",
       "                                      Retrieved Files  Avg Similarity  \\\n",
       "0   ENB, TOF-ARDS, ACURASYS, ESCNBC, FMWSCPARDS, S...        0.822698   \n",
       "1   ROSE, ACURASYS, ESCNBC, OSCILLATE, NBSARDS, CE...        0.854614   \n",
       "2   ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, O...        0.847302   \n",
       "3   ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, CEIIUPPSA...        0.812959   \n",
       "4       RARDS, FMWSCPARDS, DIHRFARDSNET, PAC-in-FACTT        0.817033   \n",
       "5               FACTT, FMWSCPARDS, RARDS, ARDSSRDRFMS        0.843431   \n",
       "6   HARDST, ENB, ARDSSRDRFMS, NBSARDS, CEIIUPPSARD...        0.875296   \n",
       "7   HARDST, ENB, ARDSSRDRFMS, FMWSCPARDS, NBSARDS,...        0.857474   \n",
       "8   ROSE, TOF-ARDS, ACURASYS, ESCNBC, BMIMSARDS, F...        0.853484   \n",
       "9   HARDST, ENB, OSCILLATE, BMIMSARDS, DDMLSMVICP,...        0.847682   \n",
       "10  ANNANE, CORTICUS, ADRENAL, HYPRESS, TRISS, SS3...        0.869297   \n",
       "11               PLMALDHSS, ANNANE, ADRENAL, CORTICUS        0.830495   \n",
       "12  ANNANE, CORTICUS, ADRENAL, HYPRESS, APROCCHSS,...        0.819342   \n",
       "13  VASST, CORTICUS, ANNANE, ADRENAL, HYPRESS, SS3...        0.826625   \n",
       "14                                               HEAT        0.887364   \n",
       "15  PROWESS, ULS, EDIS, CABS, LOVIT, SADASS, ALBIO...        0.849581   \n",
       "16                              ULS, ALBIOS, SS3vsSS2        0.873086   \n",
       "17         SAFE, FEAST, SS3vsSS2, SADASS, ALBIOS, DDS        0.845052   \n",
       "18                       Rivers Trial, ProCESS, ARISE        0.812549   \n",
       "19                   PROWESS-SHOCK, APROCCHSS, SADASS        0.842357   \n",
       "20  RIC, HACA-LA, TCAIHCA, TTM2, CETHACA, HACA, MP...        0.891963   \n",
       "21  RIC, HACA-LA, TCAIHCA, TTM2, HACA, TTM, THvsTN...        0.882604   \n",
       "22  RIC, HACA-LA, TCAIHCA, CETHACA, TTM2, HACA, MP...        0.879469   \n",
       "23         DIICU, AID-ICU, RUSGATICUD, RAEATICU, AMTD        0.865217   \n",
       "24         DIICU, AID-ICU, RUSGATICUD, AMTD, RAEATICU        0.815780   \n",
       "25  SPICE-III, RDSCI, DDMLSMVICP, DIICU, ESDDVCIP,...        0.845843   \n",
       "26  SPICE-III, RDSCI, ESDDVCIP, SEDCOM, EDvsLSMEND...        0.892401   \n",
       "27  SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SEDCOM...        0.892393   \n",
       "28  SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTS...        0.840727   \n",
       "29  SPICE-III, RDSCI, ESDDVCIP, EDvsLSMENDS, DDS, ...        0.870136   \n",
       "30  HARDST, ROSE, TOF-ARDS, ACURASYS, CCCARDS, BMI...        0.827539   \n",
       "31  ROSE, TOF-ARDS, ACURASYS, BMIMSARDS, OSCILLATE...        0.841921   \n",
       "32                                    THvsTN, CETHACA        0.852407   \n",
       "33  RIC, CAC, SEPSISPAM, OHCA, EXACT, MCAU, CETHAC...        0.843637   \n",
       "34  RIC, CAC, HACA-LA, OHCA, EXACT, CETHACA, BTCSC...        0.843511   \n",
       "35  SPICE-III, RDSCI, DDMLSMVICP, ESDDVCIP, SMDLTS...        0.850530   \n",
       "\n",
       "    Accuracy  Precision    Recall        F1  \n",
       "0   0.910714   0.444444  0.444444  0.444444  \n",
       "1   0.919643   0.545455  0.600000  0.571429  \n",
       "2   0.883929   0.285714  0.571429  0.380952  \n",
       "3   0.928571   0.428571  0.428571  0.428571  \n",
       "4   0.964286   0.500000  0.500000  0.500000  \n",
       "5   0.982143   0.750000  0.750000  0.750000  \n",
       "6   0.901786   0.111111  0.250000  0.153846  \n",
       "7   0.857143   0.083333  0.166667  0.111111  \n",
       "8   0.883929   0.166667  0.400000  0.235294  \n",
       "9   0.857143   0.083333  0.166667  0.111111  \n",
       "10  0.928571   0.666667  0.545455  0.600000  \n",
       "11  0.875000   1.000000  0.222222  0.363636  \n",
       "12  0.991071   1.000000  0.857143  0.923077  \n",
       "13  0.964286   0.636364  1.000000  0.777778  \n",
       "14  0.991071   1.000000  0.500000  0.666667  \n",
       "15  0.910714   0.250000  0.750000  0.375000  \n",
       "16  0.973214   1.000000  0.500000  0.666667  \n",
       "17  0.946429   0.166667  0.500000  0.250000  \n",
       "18  0.964286   0.666667  0.400000  0.500000  \n",
       "19  0.973214   0.666667  0.500000  0.571429  \n",
       "20  0.946903   0.777778  0.636364  0.700000  \n",
       "21  0.938053   0.750000  0.545455  0.631579  \n",
       "22  0.938596   0.777778  0.583333  0.666667  \n",
       "23  0.937500   1.000000  0.416667  0.588235  \n",
       "24  0.928571   1.000000  0.384615  0.555556  \n",
       "25  0.910714   1.000000  0.411765  0.583333  \n",
       "26  0.892857   0.875000  0.388889  0.538462  \n",
       "27  0.910714   0.888889  0.470588  0.615385  \n",
       "28  0.919643   0.888889  0.500000  0.640000  \n",
       "29  0.901786   0.857143  0.375000  0.521739  \n",
       "30  0.866071   0.066667  0.500000  0.117647  \n",
       "31  0.875000   0.000000  0.000000  0.000000  \n",
       "32  0.964286   0.000000  0.000000  0.000000  \n",
       "33  0.923077   0.100000  1.000000  0.181818  \n",
       "34  0.895652   0.000000  0.000000  0.000000  \n",
       "35  0.928571   0.750000  0.500000  0.600000  "
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "BM_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Numerical Results:\n",
      "Accuracy:  0.925\n",
      "Precision: 0.561\n",
      "Recall:    0.466\n",
      "F1 Score:  0.453\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x600 with 2 Axes>"
      ]
     },
     "metadata": {
      "image/png": {
       "height": 588,
       "width": 1188
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Print numerical results\n",
    "print(\"\\nNumerical Results:\")\n",
    "print(f\"Accuracy:  {BM_df['Accuracy'].mean():.3f}\")\n",
    "print(f\"Precision: {BM_df['Precision'].mean():.3f}\")\n",
    "print(f\"Recall:    {BM_df['Recall'].mean():.3f}\")\n",
    "print(f\"F1 Score:  {BM_df['F1'].mean():.3f}\")\n",
    "\n",
    "# Plot the metrics and ROC curve\n",
    "metrics_plot = plot_metrics_and_roc(\n",
    "    BM_df, score_column=\"Avg Similarity\", threshold=0.85\n",
    ")\n",
    "metrics_plot.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {
      "image/png": {
       "height": 589,
       "width": 990
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Select relevant columns\n",
    "metrics = [\"Accuracy\", \"Precision\", \"Recall\", \"F1\"]\n",
    "means = BM_df[metrics].mean()\n",
    "stds = BM_df[metrics].std()\n",
    "\n",
    "# Set up the plot\n",
    "plt.figure(figsize=(10, 6))\n",
    "x = np.arange(len(metrics))\n",
    "bar_width = 0.6\n",
    "\n",
    "# Create bar chart with error bars\n",
    "bars = plt.bar(\n",
    "    x, means, yerr=stds, capsize=8, color=\"skyblue\", width=bar_width, edgecolor=\"black\"\n",
    ")\n",
    "\n",
    "# Add larger and bolder value labels above bars\n",
    "for i, (mean, std) in enumerate(zip(means, stds)):\n",
    "    plt.text(\n",
    "        i,\n",
    "        mean + std + 0.02,\n",
    "        f\"{mean:.3f}\",\n",
    "        ha=\"center\",\n",
    "        va=\"bottom\",\n",
    "        fontsize=14,\n",
    "        fontweight=\"bold\",\n",
    "    )\n",
    "\n",
    "# Formatting\n",
    "plt.xticks(x, metrics, fontsize=12, fontweight=\"bold\")\n",
    "plt.ylabel(\"Score\", fontsize=12, fontweight=\"bold\", rotation=0, labelpad=30)\n",
    "\n",
    "plt.ylim(0, 1)\n",
    "plt.grid(axis=\"y\", linestyle=\"--\", alpha=0.7)\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {
      "image/png": {
       "height": 589,
       "width": 989
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Select relevant columns\n",
    "metrics = [\"Accuracy\", \"Precision\", \"Recall\", \"F1\"]\n",
    "means = BM_df[metrics].mean()\n",
    "stds = BM_df[metrics].std()\n",
    "\n",
    "# Set up the plot\n",
    "plt.figure(figsize=(10, 6))\n",
    "x = np.arange(len(metrics))\n",
    "bar_width = 0.6\n",
    "\n",
    "# Create bar chart with error bars\n",
    "bars = plt.bar(\n",
    "    x, means, yerr=stds, capsize=8, color=\"skyblue\", width=bar_width, edgecolor=\"black\"\n",
    ")\n",
    "\n",
    "# Add value labels at the same vertical position for all bars\n",
    "label_y_position = 0.07  # fixed position near the bottom\n",
    "\n",
    "for i, mean in enumerate(means):\n",
    "    plt.text(\n",
    "        x[i],\n",
    "        label_y_position,\n",
    "        f\"{mean:.3f}\",\n",
    "        ha=\"center\",\n",
    "        va=\"bottom\",\n",
    "        fontsize=14,\n",
    "        fontweight=\"bold\",\n",
    "        color=\"black\",\n",
    "    )\n",
    "\n",
    "# Formatting\n",
    "plt.xticks(x, metrics, fontsize=12, fontweight=\"bold\")\n",
    "plt.ylim(0, 1)\n",
    "plt.grid(axis=\"y\", linestyle=\"--\", alpha=0.7)\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {
      "image/png": {
       "height": 589,
       "width": 989
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Synthesis results from image\n",
    "metrics = [\"Precision\", \"Recall\", \"F1\", \"Semantic Similarity\"]\n",
    "means = [0.42, 0.42, 0.38, 0.64]\n",
    "stds = [0.45, 0.44, 0.40, 0.25]\n",
    "\n",
    "# Set up the plot\n",
    "plt.figure(figsize=(10, 6))\n",
    "x = np.arange(len(metrics))\n",
    "bar_width = 0.6\n",
    "\n",
    "# Create bar chart with error bars\n",
    "bars = plt.bar(\n",
    "    x, means, yerr=stds, capsize=8, color=\"skyblue\", width=bar_width, edgecolor=\"black\"\n",
    ")\n",
    "\n",
    "# Formatting\n",
    "plt.xticks(x, metrics, fontsize=12, fontweight=\"bold\")\n",
    "plt.ylim(0, 1)\n",
    "plt.grid(axis=\"y\", linestyle=\"--\", alpha=0.7)\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
